

viruses-1206190

How do enveloped viruses exploit the secretory proprotein convertases to regulate infectivity and spread?

Nabil G. Seidah^{1*}, Antonella Pasquato², and Ursula Andréo¹

¹ Laboratory of Biochemical Neuroendocrinology Montreal Clinical Research Institute (IRCM, affiliated to the University of Montreal) 110 Pine Ave west, Montreal, QC, H2W1R7, Canada

² Antonella Pasquato, Department of Industrial Engineering, University of Padova, Via Marzolo 9, Padova 35131, Italy.

¹ Affiliation 1: seidahn@ircm.qc.ca

¹ Affiliation 1: Ursula.Andreo@ircm.qc.ca

² Affiliation 2: Antonella.pasquato@gmail.com

*To whom correspondence should be addressed: seidahn@ircm.qc.ca, Tel: 514 987 5609

Abstract

Inhibition of the binding of enveloped viruses surface glycoproteins to host cell receptor(s) is a major target of vaccines and constitutes an efficient strategy to block viral entry and infection of various host cells and tissues. Cellular entry usually requires fusion of the viral envelope with host plasma membranes. Such entry mechanism is often preceded by “priming” and/or “activation” steps requiring limited proteolysis of the viral surface glycoprotein to expose a fusogenic domain for efficient membrane juxtapositions. The 9-membered family of Proprotein Convertases related to Subtilisin/Kexin (PCSK) serine proteases (PC1, PC2, Furin, PC4, PC5, PACE4, PC7, SKI-1/S1P and PCSK9) participate in post-translational cleavages and/or regulation of multiple secretory proteins. The type-I membrane-bound Furin and SKI-1/S1P are the major convertases responsible for the processing of surface glycoproteins of enveloped viruses. Stefan Kunz has considerably contributed to define the role of SKI-1/S1P in the activation of arenaviruses causing hemorrhagic fever. Furin was recently implicated in the activation of the spike S-protein of SARS-CoV-2 and Furin-inhibitors are being tested as antivirals in COVID-19. Other members of the PCSK-family are also implicated in some viral infections such as PCSK9 in Dengue. Herein, we summarize the various functions of the PCSKs and present arguments whereby their inhibition could represent a powerful arsenal to limit viral infections causing the present and future pandemics.

Keywords: Enveloped Virus; Proprotein Convertases; Furin; SKI-1/S1P; PCSK9; SARS-CoV-2; COVID-19; Pandemic

1. Introduction

Infectious diseases that threatened the life of humans since at least the Neolithic times, are believed to have started around 12,000 years ago, when roaming human hunter-gatherers became sedentary and settled into small camps and villages to domesticate animals and cultivate crops [1, 2]. The domestication of animals and their proximity to humans favored the transmission of animal-human (zoonotic) diseases. The latter implicated various infectious microorganisms such as bacteria, fungi, parasites, and viruses. Some of these pathogens caused widespread disease worldwide with “pandemic proportions” resulting in the death a significant fraction of the human population.

The earliest recorded pandemic disease, called Antonine Plague (A.D. 165-180) resulted from an infectious smallpox or measles virus and led to ~5 million (M) deaths throughout the Roman empire (~10% of the empire’s population). The next three big pandemics were caused by deadly bacterial (*Yersinia pestis*) infections. The first was the Justinian’s Plague (A.D. 541-542), which resulted in 5-10 M fatalities, was traced to China and northeast India, The bacterial infection was transmitted *via* land and sea trade routes to Egypt where it entered the Byzantine Empire through Mediterranean ports. The second was also caused by the same gram-negative bacteria transmitted from rats *via* infected fleas to humans and was at the origin of the bubonic/pneumonic plague (black death; A.D. 1347-1351), which resulted in the highest number of fatalities ever (200 M). The third was a major bubonic plague pandemic that began in Yunnan, China, in 1855, spread to all inhabited continents leading to 12-15 M+ deaths in India and China, with about 10 M killed in India alone. The Smallpox virus (*Variola*, A.D. 1520) killed more than 56 M people over the years resulting in the decimation of 90% of Native Americans and 400,000 death/year in Europe in the 19th century. This virus must have circulated for a long time since signs of smallpox have been found in Egyptian mummies, including Ramses V, who died in 1157 B.C. The deadliest pandemic virus in the 20th century (A.D. 1918-1919) was traced to an H1N1 variant of the flu virus (Spanish Flu) and resulted in 50 M+ death worldwide close to the end of the first world war. This virus spread between the soldiers in the war trenches in Europe and was transmitted to the general population when they came back home. Such a deadly pandemic never went away and is still causing problems today. Finally, another persisting pandemic that has hit the world starting in 1981 is due to HIV retroviral infections causing AIDS, leading to more than 35 M+ death worldwide. The latest ongoing viral-related pandemic that started in December 2019 causes a coronavirus-associated disease (called COVID-19) due to SARS-CoV-2 infections [3], which so far have resulted in more than 2.8 M+ death worldwide and against which we now have access to various efficient vaccine formulations [4-6].

From the above summary it is apparent that a substantial proportion of the deadly newly emerging and re-emerging diseases in the past century have been of viral origin [6]. While not all viruses have envelopes, e.g., enteric RNA viruses [7], the majority (RNA & DNA viruses and retroviruses) have a viral envelope that protects the genetic material in their life cycle when traveling between host cells. The envelopes are typically derived from portions of the host cell membranes (phospholipids and proteins) but include some viral glycoproteins. Glycoproteins on the surface of the envelope serve to identify and bind to receptor sites on the host's membrane. The viral envelope then fuses with the host's cell membrane [8], allowing the capsid and viral genome to enter the host. Another mechanism of virus spread requiring fusion is the formation of syncytia through cell-to-cell fusion. An infected cell harboring the glycoprotein on the plasma membrane

can fuse with an adjacent cell forming polynucleated infected cells called syncytia. This mechanism allows virus spread while limiting the release of virus in the extracellular milieu.

The proprotein convertases (PCs; genes *PCSKs*) constitute a family of nine secretory serine proteases that regulate various processes in both health and disease states [9]. Seven basic amino acid (aa)-specific convertases (PC1, PC2, Furin, PC4, PC5, PACE4 and PC7) cleave precursor proteins at single or paired basic amino acids after the general motif (K/R)-X_n-(K/R)↓, where X_n= 0, 2, 4 or 6 spacer X residues [9, 10]. The 8th member (SKI-1/S1P) cleaves precursor proteins at R-X-Aliphatic-Z↓, where X is any residue except Pro and Cys, and Z is any aa except Val, Pro, Cys or Glu [11-15]. The last member PCSK9 cleaves itself once, but its inhibitory prodomain remains non-covalently attached rendering it inactive as a protease *in trans*, but rather it can act as a chaperone escorting some surface receptors (e.g., LDLR and MHC-class I receptor) toward lysosomes for degradation [16-19].

Through proteolysis, PCs are responsible for the activation and/or inactivation of many secretory precursor proteins, including viral surface glycoproteins [9, 10, 20] (Table 1).

Table 1. Families of pathogenic viruses that depend on the basic aa-specific proprotein convertases for host cell entry. RT = reverse transcriptase.

Family	Virus	Capsid	Genome
<i>Retroviridae</i>	HIV, Leukemia viruses	Enveloped	Linear ssRNA (-), RT
<i>Flaviridae</i>	HCV, Dengue, Zika, West Nile	Enveloped	Linear ssRNA (+)
<i>Togaviridae</i>	Chikungunya	Enveloped	Linear ssRNA (+)
<i>Coronaviridae</i>	SARS-CoV-1,2, MERS	Enveloped	Linear ssRNA (+)
<i>Filoviridae</i>	Ebola, Marburg	Enveloped	Linear ssRNA (-)
<i>Orthomyxoviridae</i>	Avian Influenza H5N1	Enveloped	Linear ssRNA (-)
<i>Paramixoviridae</i>	Measle, RSV, Nipah, MPV	Enveloped	Linear ssRNA (-)
<i>Hepadnaviridae</i>	Hepatitis B	Enveloped	Linear ssDNA (-), RT
<i>Herpesviridae</i>	Herpes, CMV, Varicella-Zoster	Enveloped	Linear dsDNA
<i>Papillomaviridae</i>	HPV	Naked	Circular dsDNA

Because of their critical functions, PCs, especially the ubiquitously expressed Furin [21] and SKI-1/S1P [11], are implicated in many viral infections *via* specific cleavages of envelope glycoproteins, a condition that allows not only the fusion of the viral lipid envelope with host cell membranes [9], but also for cell-to-cell fusion forming syncytia of certain viruses leading to important cytopathogenic effects [22, 23].

In this review, we will summarize our knowledge of the role of enzymatic cleavage by proprotein convertases and type-II transmembrane serine proteases required to facilitate virus entry through fusion as well as innate antiviral strategy that the host deploys to counteract this step. A number of excellent reviews have appeared on the importance of cleavage of the surface glycoproteins of enveloped viruses in productive infections [24, 25]. Herein, we will mostly concentrate on the roles of the proprotein convertases [9] in this process and emphasize the seminal contributions of

the group of **Stefan Kunz** in the analysis of the function of SKI-1/S1P in the activation of arenaviruses causing hemorrhagic fever.

2. Proprotein convertases and enveloped viruses

2.1 Furin in viral infections and pathogenicity

Furin is the third and best characterized member of the PCSK family of secretory convertases. It cleaves at basic amino acid motifs and recognizes a prototypical sequence R-X-(K/R)-R↓ [10]. The presence of this Furin-like motif in viral envelope glycoproteins constitutes a way to activate the fusion-dependant entry of several viruses such as HIV gp160, influenza hemagglutinin (**Table 2**), and some coronaviruses spike proteins [26, 27].

Table 2. Various enveloped viruses and the sequences of surrounding their surface glycoprotein cleavage sites by Furin-like proprotein convertases.

Virus	Glycoprotein	P8	P6	P4	P2	↓	P2'
HIV	gp160		V Q	R E	K R	A	V
Influenza virus H5	HA		R K	R K	K R	G	L
Avian H5N1 A/HK/97	HA	R E	R R	R K	K R	G	L
Avian H5N1 TKY/ENG	HA	N T	P Q	R K	K R	G	L
Human CMV	gB		H N	R T	K R	S	T
Human MPV	F Protein		N P	R Q	S R	F	V
Human RSV	F Protein		K K	R K	R R	F	L
Dengue Virus (DENG2)	PrM		H R	R E	K R	S	V
Ebola Virus	gp160		G R	R T	R R	E	A
Chikungunya (CHIKV)	E3E2		P R	R Q	R R	S	I
Zika Virus	PrM		A R	R S	R R	A	V
SARS-CoV-2	S		S P	R R	A R	S	V

In 1992, Furin was identified to be the cellular protease cleaving hemagglutinin of both fowl plague virus (FPV) and influenza virus, as well as the HIV glycoprotein gp160 into gp120 and gp41 [28, 29]. The presence of a Furin cleavage sequence can shift the pathogenicity of certain viruses from non-virulent to virulent. For instance, Newcastle disease virus (NDV) fusion protein contains only a monobasic cleavage site, while the virulent NDV fusion protein possess a polybasic sequence of amino acids that can be cleaved by Furin [30]. Similarly, the acquisition of a Furin cleavage site has been linked to the high pathogenicity of avian influenza [31], especially for the Hong Kong variant [32] with an insertion of 4 amino acids N-terminal to the Furin-site (**Table 2**), resulting in a very efficient cleavage by more than one convertase, such as Furin, PC5 and PC7 [33]. Other pathogenic influenza virus do not possess a Furin cleavage site and rely on trypsin-like proteases, e.g., HAT and TMPRSS2 [34]. The expression of these enzymes is restricted to the

upper respiratory tract [35], while Furin is ubiquitously expressed and the acquisition of a Furin-like site enhances the cellular tropism of influenza. However, the presence of a polybasic Furin-like cleavage site is not the only determining factor for cleavage by Furin, as the amino-acids adjacent to the Furin-like sequence are important too, as described in **Table 2**. Furthermore, the presence of oligosaccharides near the cleavage site can prevent processing [36], unless it is compensated by an increased number of basic residues as described in the non-pathogenic variant of influenza hemagglutinin A of H5N2 [37].

Aside from glycoproteins from NDV and influenza hemagglutinin, HIV glycoprotein, as well as other retrovirus glycoproteins such as Rous sarcoma virus and murine leukemia virus are cleaved by Furin. Interestingly, these glycoproteins form trimers and some virus assemble with un-cleaved glycoprotein that remain either inactive or can be cleaved at the plasma membrane. The Furin-specific cleavage of gp160 in HIV-1 has been described as dispensable as other proprotein convertases [38] could substitute for Furin in some tissues, and plasmin could activate the gp160 at the plasma membrane. However, these hypotheses remain to be validated *in vivo* in human.

Human metapneumovirus (hMPV) is a paramyxovirus responsible for acute respiratory tract infections which can result in hospitalization of both children and adults. We showed that blocking the activity of the protease-activated receptor 1 (PAR1), a G-coupled receptor, induced by inflammation, protects against hMPV infections [39]. Furthermore, Furin activates the envelope F-protein of hMPV by cleavage at **NPRQSR₁₀₂↓FV** (**Table 2**) [39]. Unexpectedly, PAR1 itself potently inhibits cellular Furin activity [40]. Indeed, PAR1 exhibits in its second luminal loop a Furin-like motif (**PRSFLLR₄₆-NP**) with a P1 and P6 Arg and is cleaved by PC5A and PACE4 but not by Furin. The presence of an Asn₄₇ at the P1' site rather made it a potent Furin-inhibitor that binds its catalytic subunit and sequesters the [PAR1-Furin] complex in the *trans*-Golgi network (TGN), thereby inactivating Furin and preventing PAR1 from reaching the cell surface [40]. The overexpression of PAR1 has been described in the brain upon neuroinflammation and in patients with neurocognitive disorders associated with HIV infection (HAND) [40]. Interestingly, while PAR1 binds and inhibits Furin, PAR2 is cleaved by Furin at the motif **RSSKGR₃₆↓SL**, which also exhibits a P1 and P6 Arg but a favorable Ser at P1' and Leu at P2' (**Table 2**) [36]. Recently, another strategy of viral host-cell defense has been identified. Guanylate-binding proteins (GBPs) are interferon stimulated genes. Upon HIV infection, the cytosolic GBP2 and 5 expression are induced and these proteins can bind the cytosolic tail of Furin and prevent its trafficking beyond the *cis/medial* Golgi, thus keeping it in an inactive state bound to its inhibitory prodomain. This effectively inhibits the Furin processing of gp160 into gp120 and gp41 [24, 41]. Thus, while PAR1 is the first secretory endogenous natural inhibitor of Furin that blocks its enzymatic activity and prevents its exit from the TGN, the cytosolic GBP2,5 also inhibit Furin activity by blocking it in the *cis/medial* Golgi in an inactive state.

Another family of viruses requiring Furin are the *filoviridae*. Marburg and Ebola are enveloped single negative strand RNA virus of the *filoviridae* family. These viruses are highly pathogenic in human causing hemorrhagic fever with a very high mortality rate. The glycoprotein of Marburg and Ebola (GPs) are cleaved by Furin into GP1 containing the receptor binding domain (RBD) and membrane-bound GP2 [42]. Pathogenic viruses of the family possess a Furin-like cleavage site, but experiments design to establish the role of Furin in pathogenicity indicated that Furin cleavage is not required for replication in cell culture [43] and disease severity in non-human primates [44]. A recent work identified a new Furin site in Ebola GP that requires N-glycosylation to be processed

[45]. Interestingly, MARCH8 a member of the Membrane-associated RING-CH-type 8 (MARCH8) that has been described to have broad antiviral activity against several viruses, can inhibit Furin by forming a complex with the GP and Furin thereby sequestering it in the Golgi, and preventing the maturation of the viral particles [46]. This is a third example of endogenous Furin-inhibitors that sequester the enzyme in a subcellular Golgi compartment where it remains inactive.

The Flaviviruses envelope also requires Furin to get activated. The first evidence was reported for Tick Borne Encephalitis virus. Flavivirus are enveloped positive strand RNA viruses. Their surface protein are composed of a heterodimer formed by prM and E [47]. The immature prM is cleaved by Furin at GSRTRR₂₀₅↓SV before the viral particles are released from the cell. The cleavage allows fusion and is required for infectivity. An acidic pH is required to promote a change of conformation of the heterodimer to facilitate Furin cleavage. While, the cleavage of prM into M is inefficient especially for Dengue virus (HRREKR₂₀₅↓SV) (**Table 2**), likely due to the presence of a Glu at P3 [25], Furin has been confirmed to be required for infectivity of Dengue virus *in vitro* by using LoVo cells that are Furin deficient [48]. Additionally, the role of Furin in the antibody-dependent-enhancement (ADE) of Dengue virus infection is intriguing. ADE is the mechanism by which the immunisation against Dengue could exacerbate the pathogenicity of Dengue in the context of a second infection. This has been explained by the fact that the binding of antibodies to an immature particle could enhance its infectivity. Interestingly, while Furin inhibition has been described to block anti-Envelope dependant enhancement [49], antibodies against prM (uncleaved by Furin) allow tissue entry of immature particles [50]. Recently, broadly neutralizing monoclonal antibodies were reported to protect against multiple tick-borne flaviviruses (TBFVs) [51], opening the way to the design of vaccines and antibody therapeutics against clinically relevant TBFVs.

Chikungunya virus (CHIKV) is a mosquito-transmitted α -virus that causes in humans an acute infection characterized by polyarthralgia, fever, myalgia, and headache. Since 2005 this virus has been responsible for an epidemic outbreak of unprecedented magnitude. By analogy with other α -viruses, it is thought that cellular proteases are able to process the viral precursor protein E3E2 to produce the receptor binding E2 protein that associates as a heterodimer with E1. Destabilization of the heterodimer by exposure to low pH allows viral fusion and infection. We demonstrated that membrane-bound Furin but also PC5B can process E3E2 from African CHIKV strains at the HRQRR₆₄₂↓ST site, whereas a CHIKV strain of Asian origin is cleaved at RRQRR₆₄₂↓SI (**Table 2**) by membranous and soluble Furin, PC5A, PC5B, and PACE4 but not by PC7 or SKI-1/S1P [52]. This cleavage was also observed in CHIKV-infected cells and could be blocked by Furin inhibitor decanoyl-RVKR-chloromethyl ketone. This inhibitor was compared with chloroquine for its ability to inhibit CHIKV spreading in myoblast cell cultures, a cell-type previously described as a natural target of this virus [52]. We observed an additive effect of dec-RVKR-cmk and chloroquine, supporting the concept that these two drugs act by essentially distinct mechanisms. The combinatory action of chloroquine and dec-RVKR-cmk led to an almost total suppression of viral spread and yield [52].

Furin cleavage of viral glycoproteins of the *Herpesviridae* family have been reported for Herpes simplex virus 1 and 2 and Varicella Zoster (**Table 1**) contributing to the pathogenesis of the later *in vivo* [53, 54]. Finally, while Furin cleaves many glycoproteins, its activity is required for other viral proteins such as for Hepatitis B virus (HBV) core antigen. For reviews see [24, 25].

HIV-1 encodes four accessory gene products – Vpr, Vif, Vpu and Nef – which are thought to collectively manipulate host cell biology to promote viral replication, persistence and immune escape [55]. Increasing evidence suggests that extracellular Vpr could contribute to HIV pathogenesis through its effect on bystander cells. Soluble forms of Vpr have been detected in the sera and cerebrospinal fluids of HIV-1-infected patients, and *in vitro* studies have implicated extracellular Vpr as an effector of cellular responses, including G2 arrest, apoptosis and induction of cytokines and chemokines production, presumably through its ability to transduce into multiple cell types. Thus, Vpr is a true virulence factor and is a potential and promising target in different strategies aiming to fight infected cells including latently HIV-infected cells [56]. While Furin is clearly implicated in the processing activation of multiple viral surface glycoproteins including gp160 of HIV-1, other cell-surface associated convertases such as PC5A and PACE4 [9, 57] seem to negatively regulate the activity of the HIV-1 by cleavage-inactivation of secreted Vpr at RQRR₈₈↓ [58]. PC-mediated processing of extracellular Vpr results in a truncated Vpr product that was defective for the induction of cell cycle arrest and apoptosis when expressed in human cells [58]. Thus, inhibitors of PC5/PACE4 may enhance HIV-1 virulence, and Furin-specific inhibitors would restrict HIV-1 infectivity, without affecting Vpr inactivation by PC5A/PACE4.

2.2 Coronavirus infections, including SARS-CoV-2

There are 7 known human coronaviruses (CoV), which are enveloped positive-stranded RNA viruses belonging to the order *Nidovirales* and are mostly responsible for upper respiratory tract infections. All these coronaviruses exhibit a “crown-like” structure composed of a trimeric spike (S) protein. The S-protein is a ~180–200 kDa type I transmembrane protein, with the N-terminus facing the extracellular space and anchored to the viral membrane *via* its transmembrane domain followed by a C-terminal short tail facing the cytosol [59]. During infection, the trimetric S-protein is first processed at the “priming site” S1/S2 by host cell proteases, separating the N-terminal S1 domain that binds a specific host cell receptor(s) *via* its receptor binding domain (RBD), and the C-terminal membrane-bound S2 domain involved in viral entry through fusion at the plasma membrane after cleavage. S1 and S2 have been described to remain non-covalently bound therefore protecting the fusion peptide from being exposed too early before the membranes can actually fuse. Four coronaviruses are now endemic in the human population and cause mild disease, including the α -coronaviruses HCoV-229E and HCoV-NL63 and β -coronaviruses HCoV-OC43 and HCoV-HKU1 [23]. Interestingly, the insertion of a more favourable S1/S2 Furin-like site of the neuro-invasive HCoV-OC43 (RRSRR₇₅₈↓AI) resulted in the establishment of less pathogenic but more persistent viral infections in the brain [26].

In the last 18 years three new highly pathogenic human β -coronaviruses appeared, SARS-CoV-1 in 2002–2003, MERS-CoV in 2013, and SARS-CoV-2 (**Table 2**) at the end of 2019. The first two were associated with severe human pathologies, such as pneumonia and bronchiolitis, and even meningitis in more vulnerable populations [60]. However, SARS-CoV-1 was rapidly contained and MERS-CoV only spread from dromedary to human and no human to human transmissions were reported. The RBDs of the S1-subunits of SARS-CoV-1 and MERS-CoV recognise angiotensin-converting enzyme 2 (ACE2) [61] and dipeptidylpeptidyl 4 (CD26/DPP4) [62] as their entry receptors, respectively. While the single basic Arg at the S1/S2 site of SARS-CoV-1 (TVSLLR₆₆₇-ST) does not contain a Furin-like site, that of MERS-CoV does (TPRSVR₇₅₁↓SV). Indeed, the priming of SARS-CoV-1 in the lung is thought to be performed by elastase [63, 64], whereas MERS-CoV processing at S1/S2 is thought to be mostly performed by

Furin and possibly by TMPRSS2, a type-II membrane-bound serine protease [65, 66]. The S2-product generated following S1/S2 cleavage contains a second proteolytic site (S2'), followed by a fusion peptide (FP) and two heptad-repeat domains preceding the transmembrane domain (TM) and cytosolic tail. Cleavage at S2' trigger membrane fusion and is essential for efficient viral infection. The S2' cleavage sites in SARS-CoV-1 (PTKR₇₉₇↓SF) and MERS-CoV (RSAR₈₈₇↓SA) suggest that both could be cleaved by a Furin-like enzyme, but the single Arg-specific enzyme TMPRSS2 has solely been proposed to cleave both spike glycoproteins at S2' [67].

The Furin-like S2' cleavage site at KR₇₉₇↓SF with P1 and P2 basic residues and a P2' hydrophobic Phe [9], is identical between the SARS-CoV-1 and SARS-CoV-2 (Fig. 1). In the MERS-CoV and OC43-CoV it is replaced by the less favourable Furin-like site RXXR↓SA, with P1 and P4 basic residues, and an Ala (not hydrophobic) at P2'. However, in other less pathogenic circulating human coronaviruses, the S2' cleavage site only exhibits a Furin-unfavourable monobasic R↓S sequence [68] with no basic residues at either P2 and/or P4. Even though processing at S2' in the spike glycoprotein of SARS-CoV-2 is thought to be key in the activation of the S-protein, leading to cell-fusion and entry, multiple protease(s) might be involved in S-cleavage at different sites and subcellular compartments [69]. The ability of the Arg/Lys-specific TMPRSS2 to directly cleave at S2' was inferred from the viral entry blockade by the relatively non-specific TMPRSS2 inhibitor Camostat [70, 71]. We recently demonstrated that Furin is capable of performing both S1/S2 (PRRAR₆₈₅↓SV) (Table 2) and S2' (KPSKR₈₁₅↓SF) cleavages generating an N-terminal S1 subunit (with an RBD domain) and a C-terminal membrane bound fusogenic S2'-cleaved subunit in the presence of the Spike-glycoprotein receptor ACE2 [72]. Interestingly, binding of the RBD of the S-protein of SARS-CoV-2 to ACE2 was demonstrated to exert a conformational change that allosterically enhances the exposure of the S1/S2 site to Furin cleavage [73]. Whether it also enhances S2' exposure is not clear, but our results clearly show that Furin cleavage at S2' is enhanced in the presence of ACE2 [72]. Our data also showed that non-peptide small molecule BOS-inhibitors of Furin-like enzymes block the processing of the S-protein at both S1/S2 and S2' sites and result in a significant reduction of cell-to-cell fusion. In the presence of overexpressed TMPRSS2 together with the S-protein, the latter was cleaved into an apparently lower sized fragment than S1 (called S1') [72] released in the cell culture media, which turned out to be an authentic S1 product lacking O-glycosylation as it is generated in the endoplasmic reticulum (ER) and secreted by an unconventional pathway (*submitted*). Furthermore, overexpressed TMPRSS2 generated two C-terminal membrane bound fragments S2a and S2b, which are S2 and S2' also lacking O-glycosylation. These products may be artificially produced in the ER upon overexpression of TMPRSS2 with the S-glycoprotein. However, in co-culture conditions in which ACE2 and TMPRSS2 are expressed in acceptor cells and S-protein in donor cells we concluded that both Furin (in the TGN) and TMPRSS2 (at the cell surface) cleave S-protein into S1/S2 and S2' in the presence of ACE2 (*submitted*), but that in addition TMPRSS2 can also process and shed ACE2 into a soluble form thereby modulating viral entry and infection. In agreement, an inhibitor cocktail that combines a Furin inhibitor (BOS) with a TMPRSS2 inhibitor (Camostat) can reduce by 99% SARS-CoV-2 infectivity of lung-derived Calu-3 cells [72]. It should be noted that coronaviruses may enter the cells through fusion at the plasma membrane or following endocytosis into endosomes [74]. The versatility of strategies to penetrate the cell allow coronaviruses to depend less on the availability of the different proteases in specific cell type and in cellular compartments.

Interestingly, we previously showed that chloroquine, initially used as an antimalarial, can reduce viral infection and spread of both Chikungunya virus [52] and SARS-CoV-1 [75]. In the latter case, chloroquine was also shown to affect the N-glycosylation pattern of ACE2, the receptor of SARS-CoV-1 [75] and SARS-CoV-2 [27]. Interfering with terminal glycosylation of ACE2 may negatively influence the virus-receptor binding and abrogate infection, with further ramifications by the elevation of TGN/vesicular pH, resulting in the inhibition of infection and spread of SARS CoV-1 at clinically admissible concentrations. This may also be applicable for SARS-CoV-2, but the protective role of the less toxic hydroxychloroquine together with the antibiotic azithromycin against COVID-19 at the early infection stages remains controversial and begs for unbiased clinical trials [76].

Worldwide distribution of various SARS-CoV-2 vaccines conceived to mount an immune response against the S protein therefore blocking accessibility of the S-protein to ACE2 (<https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker>) represents an efficient strategy to prevent SARS-CoV-2 infections and eliminate the burden of the pandemic on a global scale. Time is needed to determine if these vaccines will confer a long-lasting protection. Furthermore, since April 2020 new variants of SARS-CoV-2 emerged, some of which are becoming prominent in Europe as well as North and South America. Emergence of such variants indicated an enhanced SARS-CoV-2 fitness and are thought to have increased transmissibility. Variants in the United Kingdom (B.1.1.7) [77], South Africa (B.1.351) [78], Brazil and Japan (B.1.1.248) [79] present multiple substitutions in the spike protein, some of which are common among different variants. These include critical mutations in the ACE2 binding site (e.g., N501Y and E484K) within the RBD (**Table 3**), resulting in enhanced binding affinity of S-protein to ACE2 by 2.5-fold for N501Y and 13.5-fold for [N501Y + E484K] [80].


Table 3. Amino acid changes in the S-protein of SARS-CoV-2 variants of worldwide concern covering the period of September 2020–January 2021

Variant	First identification	S-protein mutations	Worldwide Cases	# of Countries
B.1.1.7	UK Sept 2020	del69-70 HV, del144 Y, N501Y, A570D, D614G, P681H, T761I, S982A,	15.369	36
B.1.351	South Africa Oct 2020	K417N, E484K, N501Y, D614G, A701V	415	13
B.1.1.248	Brazil, Japan Jan 2021	L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I	35	4

Accordingly, it is not surprising that these variants are associated with a loss of efficacy of certain vaccines against SARS-CoV-2 [81, 82]. Amazingly, screening various artificial mutants *in vitro* showed that some mutant-combinations could result in a very worrisome 600-fold higher binding affinity of S-protein to ACE2 [80]. Thus, B.1.351 and similar spike mutations present new challenges for antibody therapy and threaten the protective efficacy of current vaccines.

While the protective effect of the vaccination on the whole world population remains incomplete, additional effective antiviral drugs that block viral entry in target cells (**Figure 1**) are still needed and could help in early treatment of the disease. Ultimately, in case of new emerging coronavirus pandemics [83], the availability of such treatments would constitute a powerful antiviral arsenal.

Figure 1: Role of protease processing in SARS-CoV-2 entry. SARS-CoV-2 can enter through fusion at the plasma membrane or by endocytosis. The processing of the spike-protein at the plasma membrane by Furin at the S1/S2 site is favored while Furin & TMPRSS2 are involved in the processing at S2', thereby inducing fusion. Furin cleavage at S1/S2 is not required to promote entry through endocytosis and Cathepsin L may cleave at S1/S2 and S2' in endosomes.



2.3 PCSK9 and viral infections

The secreted protein PCSK9, is the 9th member of the PCSKs family that autocatalytically cleaves its prodomain in the ER allowing its exit from this compartment and its secretion from cells [16], as a protease-inactive [prodomain-PCSK9] complex [84, 85]. Its high expression in liver and the presence of its gene on chromosome 1p32 [16], led to the genetic association of gain-of-function (GOF) variants of *PCSK9* with an autosomal dominant form of hypercholesterolemia [86]. This strongly suggested that PCSK9 may play a critical role in low density lipoprotein-cholesterol (LDLc) regulation. Indeed, while GOF variants were associated with high levels LDLc [86], the reverse was true for loss-of-function (LOF) variants [87]. Mechanistically, circulating PCSK9 was shown to reduce the levels of liver LDL-receptor (LDLR) protein by sorting the PCSK9-LDLR complex to lysosomes for degradation, implicating an interaction of the PCSK9 catalytic domain with the EGF-A domain of the LDLR [84, 88, 89].

In a first study, we showed that PCSK9 can reduce HCV infection of HuH7 cell using the cell culture-derived HCV clone JFH1 (genotype 2a). We demonstrated that the effect was due to the PCSK9-induced decrease of the LDLR protein levels on the surface of HuH7 cells. Also, HCV

upregulates the expression of LDLR *in vitro* and in chronic infected liver [90], likely due to an upregulation of the LDLR promotor activity through SREBPs and a decreased expression of PCSK9 [91]. Befittingly, Alirocumab, a therapeutic human monoclonal antibody (mAb) to PCSK9 used to treat hypercholesterolemia through an increase of cell surface LDLR failed to reduce HCV entry and infectivity in hepatocyte *in vitro* [92].

Additionally, the role of PCSK9 in the course of the natural HCV infection is not fully understood. We showed that HCV genotype 3 (G3) infected patients with high viral load have low levels of PCSK9 and LDLc compared to HCV genotype 1 (G1) infected patients, suggesting that the particular interplay between HCV and lipid metabolism and PCSK9 might be genotype specific [93]. In contrast, in a retrospective study PCSK9 levels were found to be elevated especially in chronic genotype 2 (G2) HCV patients with or without hepatocellular carcinoma (HCC), but the increased PCSK9 levels were not significantly associated with changes in LDLc [94]. Overall, the data reported on a potential role of PCSK9 in HCV infection illustrate the complex interplay between HCV and lipid metabolism.

Dengue virus (DENV), a single positive-stranded RNA virus of the family Flaviviridae, is transmitted to human by the urban-adapted *Aedes* mosquitoes. It is estimated that 400 M+ individuals are infected with 1 of the 4 types of the DENV [95]. The DENV surface glycoprotein prM-E complex needs cleavage by Furin-like enzymes to remove the prodomain of the envelope glycoprotein prM and allow the formation of the activated M-E complex and acquisition of infectivity. However, unlike cleavage of the prM of other flaviviruses, cleavage of DENV prM is incomplete in many cell lines, likely due to the negative influence of the aspartic acid (D) at the P3 position of the processing site HRRDKR↓SV at the pr-M junction (Table 2) [96]. Therefore, it is not surprising that inhibitors of Furin-like enzymes, while significantly reducing viral entry, did not completely block viral infections [97] (*unpublished results*).

Very recently, we showed that DENV infection reduces the antiviral response of the host liver hepatocytes. Thus, DENV infection induces expression of PCSK9, thereby reducing cell surface levels of LDLR and LDLc uptake resulting in enhanced *de novo* cholesterol synthesis and its enrichment in the ER. In turn, high levels of ER cholesterol suppressed the phosphorylation and activation of the ER-resident stimulator of interferon (IFN) gene (STING), leading to reduction of type I interferon (IFN) signalling through antiviral IFN-stimulated genes (ISGs) [98]. This was supported by the detection of elevated plasma PCSK9 levels in patients infected with DENV resulting in high viremia and increased severity of plasma leakage. This unexpected role of PCSK9 in dengue pathogenesis, led us to test the effect of inhibition of PCSK9 function by the mAb Alirocumab. Befittingly, this treatment resulted in higher LDLR levels and lower viremia. Our data suggested that PCSK9 inhibitors could be a suitable host-directed treatment for patients with dengue [98], possibly in combination with Furin-like inhibitors.

2.4 Implications of SKI-1/S1P in viral infections

The 8th member of the proprotein convertase family was discovered in 1998/1999 as a type-I membrane-bound protease called site-1 protease (S1P) [99] or alternatively subtilisin-kexin isozyme-1 (SKI-1) [11]. Since then, it is commonly named SKI-1/S1P and its gene is given the name Membrane-Bound Transcription-factor Site-1 Protease (*MBTPS1*) [9]. Extensive studies of its cleavage specificity revealed that it recognizes the general motif **R-X-Aliphatic-Z**↓, where X

is any residue except Pro and Cys, and Z is any aa (best Leu) except Val, Pro, Cys or Glu [11-15] (Table 4).

Table 4. SKI-1/S1P processing sites of various cellular substrates and those of enveloped viruses with emphasis on the sequences surrounding their surface glycoprotein cleavage sites.

Substrate		P8		P6		P4		P2		↓	P2'		P4'	
CELLULAR	h Pro-SKI-1 site B	R	K	V	F	R	S	L	K	Y	A	E	S	
	h Pro-SKI-1 site B'	V	T	P	Q	R	K	V	F	R	S	L	K	
	h Pro-SKI-1 site C	R	H	S	S	R	R	L	L	R	A	I	P	
	h SREBP2	S	G	S	G	R	S	V	L	S	F	E	S	
	h SREBP1	H	S	P	G	R	N	V	L	G	T	E	S	
	h ATF6	A	N	Q	R	R	H	L	L	G	F	S	A	
	h Luman	G	V	L	S	R	Q	L	R	A	L	P	S	
	m OASIS (CREB3L1)	Q	M	P	S	R	S	L	L	F	Y	D	D	
	h CREB-H	R	V	F	S	R	T	L	H	N	D	A	A	
	h pro-BDNF	K	A	G	S	R	G	L	T	S	L	A	D	
	h α/β-GlcNAc-1-pTr	K	N	T	G	R	Q	L	K	D	T	F	A	
	h FAM20C	K	H	T	L	R	I	L	Q	D	F	S	S	
	h pro-Renin receptor	I	R	K	T	R	T	I	L	E	A	K	Q	
VIRAL	Lassa Virus (LASV) GP-C	I	Y	I	S	R	R	L	L	G	T	F	T	
	CCHFV PreGn	S	S	G	S	R	R	L	L	S	E	E	S	
	LCMV GP-C	K	F	L	T	R	R	L	A	G	T	F	T	
	Junin Virus (JUNV) GP-C	Q	L	P	R	R	S	L	K	A	F	F	S	

SKI-1/S1P was first identified in our group because of its ability to cleave in the *cis/medial* Golgi brain derived neurotrophic factor (BDNF) at **R**GLT₅₇↓SL, thereby preceding the Furin cleavage in the TGN at **R**VRR₁₂₈↓HS to release mature BDNF [11]. The enzyme was then linked to the activation of several transcription factors. Among others, the sterol regulatory element binding proteins 1 and 2 (SREBP1,2; implicated in sterol and fatty acid synthesis), the type-II membrane-bound ER-stress factor ATF6, and other type-II membrane-bound substrates including at least six CREB-like basic leucine zipper transcription factors (Table 4). Other substrates identified revealed a role of SKI-1/S1P in the regulation of the kinase FAM20C that phosphorylates luminal serine residues in the secretory pathway [101], and in the activation of the α/β-GlcNAc-1-phosphotransferase that phosphorylates mannose residues in glycoproteins sorted to lysosomes (Table 4) [102]. The last identified substrate is the (pro)renin receptor which is shed by SKI-1/S1P in the bloodstream where it plays a major role in hypertension [103]. In humans, *MBTPS1* mutations are linked to the Silver–Russell syndrome (SRS) in patients affected by defective inter-organellar protein trafficking and skeletal malformations [104, 105].

The unique cleavage specificity of SKI-1/S1P puts it in a class of its own, distinct from the basic-aa specific convertases. This led to the search for possible viral glycoprotein substrates that are activated *via* a non-canonical Furin-like cleavage, possibly by SKI-1/S1P or through a combination

of both processing enzymes. Thus, SKI-1/S1P was shown to play a major role in the processing of surface glycoproteins precursors (GP-C) of infectious arenaviruses such as Lassa virus (LASV) at **RRL↓GT** (**Table 4**) [106-108], which is endemic in West Africa and is estimated to affect some 500,000 people annually resulting in several thousands death each year [109].

Interestingly, while SKI-1/S1P is predicted to be fully mature in the *cis/medial* Golgi, it can cleave the GP-C of LASV in the ER/*cis* Golgi indicating an functional activity in early secretory compartments. We speculate that forms of SKI-1/S1P that are only cleaved at the B'/B sites can already be partially active. This may be due to the fact that the optimal **RRL↓** cleavage motif [14] found in site C of the SKI-1/S1P prodomain (**Table 4**) is identical to the processing site of LASV GP-C [106, 107], representing an ideal substrate [14]. In line with this hypothesis, Stefan Kunz group found that Golgi-cleavable substrates can be processed in the ER when engineered to contain **RRL↓**, regardless the rest of the backbone protein that carries the motif [107]. The N-terminal B'/B fragment of the prodomain represents an autonomous structural and functional unit that is necessary and sufficient for folding and partial activation of SKI-1/S1P. In contrast, the C-terminal B-C fragment lacks a defined structure but is crucial for autocatalytic processing and full enzymatic activity [110]. Therefore, it is not surprising that the partial processing of the prodomain in the ER at the B'/B site is enough to confer some enzymatic activity on specific viruses with very favorable glycoprotein processing sites, e.g., LASV.

Attempts to generate vaccines against the GP-C of LASV revealed that major histocompatibility class I (MHC-I) receptors play a critical role in the T-cells response to LASV infections [111], suggesting that conditions that favor higher levels of MHC-I receptors may enhance the inflammatory response by activated macrophages following LASV infection contributing to its pathogenesis. In this context, the recent observation that PCSK9 inhibition/silencing *in vivo* enhances the levels of MHC-I *via* its PCSK9-induced degradation in endosomes/lysosomes [19] would suggest that this clinically safe treatment, though very effective in reducing hypercholesterolemia [112] and in cancer/metastasis treatments [19], may actually also enhance the contributions of the immune response to viral disease severity by exacerbating the LASV-induced inflammatory response, which represents a major hurdle in vaccine development against viral infections [113]. Thus, administration of PCSK9 inhibitors [112] would not be recommended in LASV-infected and HCV co-infected patients, where MHC-I and LDLR, respectively, play important roles in the pathogenesis.

Another GP-C activated by SKI-1/S1P includes the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) processed at **RRLA↓GT** (**Table 4**) [114-116]. In contrast to LASV, SKI-1/S1P cleaves the GP-C of LCMV in the *trans* Golgi. Of note, the **RRLA↓** motif is sufficient to direct the maturation of the glycoprotein within this late compartment. Indeed, a single point mutation of LASV GP-C engineered to replace Leu at P1 with Ala results in a glycoprotein resistant to the cleavage in the ER but sensitive to SKI-1/S1P activity much later in the secretory pathway [107, 117] (**Fig. 1**). These key findings by Stefan Kunz are important to further classify SKI-1/S1P as a unique enzyme, different from the rest of the basic aa-specific PC-members. Using the Arenaviruses as a tool, his team was able to confirm not only that SKI-1/S1P possesses a distinctive *consensus* motif but also to show that the nature of the single amino acids around the cleavage site is critical to allow the enzymatic activity within a specific sub-cellular compartment. Such behaviour in the panorama of proteases is unique and probably reflects the complex

maturation mechanism of SKI-1/S1P that Stefan Kunz unraveled, resulting in a plethora of forms retaining prodomain fragments of this enzyme.

LASV and LCMV were the first Arenaviruses found to be SKI-1/S1P dependent [106]. Since then, other members of the Old World (OW) Arenaviruses showed this distinctive feature. The GP-C of Lujo Virus (LUJV) recently isolated in a cluster of lethal hemorrhagic fever cases in Africa is an example [118]. Using a very elegant approach, Stefan Kunz showed that SKI-1/S1P processes the LUJV GP-C by engineering a luciferase sensor carrying the glycoprotein specific cleavage site **RKLM↓** [119]. Similar to Old World counterparts, the New World (NW) arenaviruses – which are endemic in the Americas – strictly depend on SKI-1/S1P for their maturation.

The JUNV transmitted by rodents is a well characterized member of the NW arenaviruses with a mortality rate of 20-30% among infected populations in Argentina [120]. The JUNV surface glycoprotein GP-C is cleaved by SKI-1/S1P at **RSLK↓AF**. The processing site was confirmed by Stefan Kunz using the luciferase sensor platform [119] (**Table 4**). Interestingly, JUNV maturation site closely resembles the C-site auto-cleavage motif of SKI-1/S1P [11] (**Table 4**). As expected, it was suggested that the JUNV envelope glycoprotein is activated in a late cellular Golgi compartments [121] where also the last steps of SKI-1/S1P maturation take place. In general, the present data suggest that arenavirus GP-Cs evolved to mimic SKI-1/S1P auto-processing sites [122, 123], likely ensuring effective cleavage and avoiding competition with cellular substrates of SKI-1/S1P [124]. Old World and clade C New World GP-Cs further possess a distinctive signature that consists in displaying an aromatic residue at position P7, which is far away from the actual cleavage site. Such aromatic residues are implicated in the molecular recognition of the counterpart Tyr₂₈₅ located on the molecular surface of the enzyme. This finding suggests that during co-evolution with their mammalian hosts, arenavirus GPCs expanded the molecular contacts with SKI-1/S1P beyond the classical four-amino-acid recognition sequences and currently occupy an extended binding pocket [108]. The specificity of the interaction between Tyr₂₈₅ of SKI-1/S1P and aromatic P7 residues found in viral but not cellular substrates makes this interaction a promising target for the development of specific antiviral drugs which should not interfere with the catalytic triad directly, thus preserving full cellular activities of SKI-1/S1P. Overall, Stefan Kunz work has brought to light the outstanding ability of Arenaviruses to exploit SKI-1/S1P in a way to optimize the molecular contacts, outmatching the enzyme natural substrates. His results should be of great value for further identification of antivirals.

The crucial role of SKI-1/S1P in the virus life cycle and therefore in the establishment of infection has been beautifully shown by a recent work by Manning and colleagues. Candid #1 (Can), derived from the pathogenic Junin virus, is a vaccine against JUNV whose use is limited to Argentina. One single mutation of the envelope glycoprotein of Candid #1 is primarily responsible for the virus attenuation by impairing an effective GP-C glycosylation that in turn drastically limits the envelope glycoprotein processing [125]. The above example relies on a variation that perturbs the recognition of the viral substrate by the cellular enzyme. In a similar fashion, we can imagine that misfunctions of SKI-1/S1P can lead to similar outcomes. Indeed, studies on mice carrying a hypomorphic mutation in the *MBTPS1* gene (woodrat) showed that arenaviruses are incapable of establishing persistent infections *in vivo* [126]. Besides natural (Candid #1) and engineered (woodrat) variants, pharmacological treatments targeting SKI-1/S1P were also shown to be effective against arenavirus spread. Different from other enveloped viruses, only the cleaved glycoprotein is incorporated into budding virions. Naked viral particles fully lacking spikes are

not infectious and cannot be primed by other proteases, e.g. during entry. Thus, SKI-1/S1P mediated maturation of arenavirus glycoproteins represents a key event and a druggable target, prompting several groups to test inhibitors against various arenaviruses [127].

SKI-1/S1P inhibitors can be grouped into three major classes:

1. Proteins: We first showed that overexpression of the prodomain alone of SKI-1/S1P as well as variants of α 1-antitrypsin can inhibit the function of this convertase [13]. The effect is striking against LASV multicycle replication [128].

2. Peptides: These include among others, tetrapeptide-chloromethylketones (CMKs) developed in our group [14] and the enediynyl peptides [129]. CMKs potently block LCMV infection [130] but their use is limited to research purposes since they are highly toxic *in vivo*.

3. Non-peptide small molecules: Because of their properties and stability, this class of inhibitors are generally preferred over others for *in vivo* use. A small molecule SKI-1/S1P inhibitor PF-429242 was developed by Pfizer [131, 132], and tested as an antiviral targeting GP-C processing and productive infection of arenaviruses. SKI-1/S1P inhibition by PF-429242 suppresses viral replication in cells infected with LASV, LCMV [133], and New World arenaviruses [134]. Interruption of drug treatment did not result in re-emergence of infection, indicating that PF-429242 treatment leads to virus extinction. Of note, Stefan Kunz found that the drug is capable of clearing LCMV from chronically infected cells with no emergence of escape variants [134]. This finding is intriguing since an LCMV mutant engineered to carry the RRRR↓ mutation is viable and fit [130]. The replacement of the wild type RRLA↓ motif with RRRR↓ does switch LCMV dependence from SKI-1/S1P to Furin. Therefore, it seems that arenaviruses are not prompted to use other members of the PCs family. The reason(s) for this selectivity of SKI-1/S1P has not yet been elucidated.

SKI-1/S1P also cleaves the glycoprotein PreGn of the Crimean Congo Hemorrhagic Fever Virus (CCHFV), a member of the *Bunyaviridae* family, at RRL↓SE [135] (**Table 4**) to release an N-terminal mucin-like domain (MLD) fused to a non-structural glycoprotein GP38 and a C-terminal fusogenic Gn-containing domain. This virus is unique since after the SKI-1/S1P processing at RRL↓, the N-terminal product is further processed at RSKR↓ by Furin-like enzymes separating the MLD from GP38 [136, 137]. Functional data further revealed that cleavage at the Furin-like RSKR↓ site is not essential for CCHFV production or cell-cell spread, but that Furin cleavage enhances virion production [137]. In contrast, processing at RRL↓ is critical for virus infectivity. Cells deficient in SKI-1/S1P produce no infectious virus, although PreGn accumulates normally in the Golgi apparatus where the virus assembles [136].

Aside from direct glycoprotein cleavage by SKI-1/S1P, indirect roles in viral infection are now being documented. In a first example while SKI-1/S1P is not implicated in the direct processing of the surface glycoprotein GP of Ebola virus (EBOV), the SKI-1/S1P activation of α/β -GlcNAc-1-phospho-transferase is required to allow cathepsins sorting to lysosomes and their promotion of EBOV assembly [138]. Thus, active cathepsins B and L in lysosomes cleave EBOV GP to remove the glycan cap and the mucin-like domains, thereby favoring binding of GP to the NPC1 receptor and priming it for fusion [138].

In a second example, loss of SKI-1/S1P activity is expected to reduce the processing of SREBP1,2 and hence reduce the levels of intracellular lipids that in turn drastically impacts on

viral infection and replication. In line with this vision, the SREBP-dependent lipidomic reprogramming represents an attractive antiviral target [139]. However, since lipids are at the crossroad of various cellular pathways/signaling, deciphering the complex mechanism(s) behind the SREBPs-mediated antiviral effects may plead different explanations. Accordingly, robust inhibitory effects on SARS-CoV-2 entry and replication are observed following *MBTPS1* silencing or inhibition of SKI-1/S1P by PF-429242 treatment ($IC_{50}=300$ nM) in cells [140]. The present evidence exclude any interference with the maturation of the envelope S-glycoprotein, which is indeed cleaved by another Proprotein Convertase, i.e. Furin [72]. Rather, this member of the *Coronaviridae* family depends on healthy cellular lipid homeostasis more than other coronaviruses through a mechanism that has not yet been fully described. Lipid droplets formation were further confirmed to be essential in SARS-CoV-2 replication and pathogenesis [141]. On the other hand, it was suggested that inhibition of SREBP2 activation (implicating SKI-1/S1P cleavage) may represent a successful strategy to avoid a possible cytokine storm event in COVID-19 patients [142, 143]. Flaviviruses represent another group of pathogens whose ability to infect is intimately associated to cholesterol and therefore SKI-1/S1P. Along this line, flaviviruses rearrange intracellular membranes and orchestrate a profound reorganization of the host cell lipid metabolism to create a favorable environment for viral multiplication. Major members of the *Flaviviridae* family are Dengue virus (DENV), hepatitis C virus (HCV), West Nile virus (WNV) and Zika virus (ZIKV). DENV is highly sensitive to SKI-1/S1P inhibitors at the late stage of the infection indicating that PF-429242 does not target virus surface glycoprotein prM processing directly, but rather regulates host cellular factors needed to synthesize lipids which are essential for suitable assembly platforms [144]. The inhibitory mechanism may be associated to a dramatic reduction in the abundance of neutral lipids and their markers which drastically impairs virus propagation. Similarly, we [145] and others [146] showed that mis-regulation of the cellular SKI-1/S1P activity is a successful strategy to eradicate HCV infection.

WNV and ZIKV were likewise shown to be sensitive to SKI/S1P inhibitors, along with structurally unrelated drugs targeting the SREBPs pathway [147]. Interestingly, we showed that SKI-1/S1P regulates HCV viral replication early in the viral lifecycle with no change in LDLR or CD81 receptors levels [145], closely resembling the effect of SKI-1/S1P inhibition in infections by SARS-CoV-2 [143]. In this scenario, indirect effects induced by SKI-1/S1P inhibition may contribute to reduce virus infection [148].

It is plausible that in the presence of PF-429242, lower cholesterol and fatty acids synthesis may upregulate the antiviral interferon (IFN) response of cells, as it was observed by PCSK9 inhibitors that would lower ER-cholesterol availability and hence active SREBP-2 levels, resulting – for example - in reduced DENV assembly [98]. Flaviviruses are somehow expected to be affected by SKI-1/S1P manipulation due to their lipid dependence during virion assembly and/or viral protein trafficking. In contrast, there are pathogens that are mainly affected in their entry step upon disrupting the normal cellular lipid distribution. This is the case of Hantaviruses, members of the family *Bunyaviridae* associated with hemorrhagic fever with renal and cardiopulmonary/pulmonary syndromes in humans. Both depletion of *MBTPS1* gene and SKI-1/S1P inactivation efficiently inhibit Hantavirus membrane fusion at or near the lipid mixing step and block cytoplasmic delivery of viral matrix protein entry. As a matter of fact, Hantavirus membrane fusion directly depends on the cholesterol abundance of the target cells [149].

It is becoming more and more evident that SKI-1/S1P is a key regulator of multiple types of viral infection. Thus, targeting such host component represents a powerful strategy to contain

multiplication and spread of viruses. In turn, this would provide the patient's immune system a window of opportunity to develop an appropriate antiviral immune response to clear the virus off. Unfortunately, the only small inhibitor available PF-429242 failed to reach clinical applications due to its poor pharmacokinetic properties [132], thus begging for a potent and safe SKI-1/S1P inhibitor as an antiviral to fight such deadly infections [127, 150-152].


3. Discussion

From the above considerations it became clear that most enveloped viruses require processing of their surface glycoproteins for productive infectivity. Enhanced pathogenicity has been associated with the apparition of a new cleavage site in certain viruses. While clearly favoring Furin cleavage [72, 153], the exact role of the acquisition of a Furin site in SARS-CoV-2 [68] and its role in the spread of the virus and/or its pathogenicity have not been adequately established. Experimental evidence is not easy to obtain. One would need to generate a virus mutant to be tested in an animal model exhibiting the multiple pathogenesises that mimic the human clinical manifestation of COVID-19. A clear advantage of SARS-CoV-2 over SARS-CoV-1 has been its ability to spread asymptomatically and with great efficiency in a large portion of the population. One can speculate that the acquisition of a Furin cleavage site has contributed to confer to SARS-CoV-2 such an advantage and to enhance the tropism of this virus, as Furin is widely expressed in most tissues, whereas TMPRSS2 implicated in SARS-CoV-1 activation [23] is more limited in its tissue expression.

A clear distinction was made between the choice of the two ubiquitously expressed convertases (i) the basic aa-specific Furin *versus* (ii) the non-basic aa specific SKI-1/S1P. The mechanistic rationale may be, in part, related to the subcellular localization of the active forms of these convertases, which are initially synthesized as zymogens in the ER that are autocatalytically activated *via* two or more cleavages of their prodomains. Thus, whereas SKI-1/S1P autocatalytically activates itself early in the ER/*cis* Golgi (B'/B cleavages), becoming maximally active in the *medial* Golgi (C/C' cleavages), Furin is first autocatalytically processed at the C-terminus of its prodomain in the ER, but still remains inactive as it is non-covalently bound to its prodomain. It is only in the TGN that Furin completely separates from its inhibitory prodomain, whereupon it processes various substrates *in trans* in the TGN, cell surface and/or endosomes [9, 20, 154, 155]. This allows the processing of a wide spectrum of substrates that are preferentially cleaved by Furin at either the cell surface neutral pH (Anthrax toxin and PCSK9) or acidic pH of the TGN (e.g., SARS-CoV-2 S-protein, Ebola Zaire pro-GP) and endosomes (e.g., Diphtheria and Shiga toxins). The same also seems to apply for SKI-1/S1P that can be partially activated at neutral pH in the ER, or much more active in the slightly acidic pH environment of the *cis/medial* Golgi (**Figure 2**). An additional selectivity is provided by the substrate itself *via* its protein folding and subcellular trafficking, whereupon some SKI-1/S1P substrates are activated in the ER (e.g., LASV GP-C) and the majority of others in the *cis/medial* Golgi (SREBPs, and multiple viral glycoproteins). Finally, one single pathogen is known to exploit both pathways; CCHFV uses both SKI-1/S1P for viral activation and Furin to enhance viral production [137].

Figure 2. Schematic representation of the cellular compartments and where Proprotein Convertases are active against viral substrates. Furin processes the coronavirus SARS-CoV-2 spike S in the TGN; SKI-1/S1P matures the arenavirus LASV and LCMV GP-Cs in the ER and

late Golgi, respectively. The cleaved viral glycoproteins reach the cell surface. Arenaviruses do incorporate only cleaved GP-C into viral budding particles since treatment with the SKI-1/S1P inhibitor PF-429242 blocks GP-C processing and its incorporation into budding particles; SARS-CoV-2 can include both cleaved and uncleaved envelope glycoprotein spike S.



In all examples described above, the link between protease(s) and pathogen is clear cut, being the surface glycoprotein matured into active forms (e.g. acquisition of fusogenic properties) to attain full infectivity. This event is visible at the cell surface and therefore easily traceable by standard biochemical techniques. In contrast, how pathogens interact with the host as well as hijack, avoid and re-programme pre-existing pathways is still a matter of study. We may identify some common strategies, keeping in mind – though – that each infectious agent leaves its own fingerprints behind. For instance, upregulation of the SKI-1/S1P-dependent SREBP1,2 pathway is a well documented example of host manipulation by Flaviviruses, since the increase of ER/Golgi lipids is critical for virion assembly, as was recently shown for Dengue virus [98]. Other viruses, e.g. SARS-CoV-2 and Hantaviruses, require cholesterol for effective entry, thereby affecting early stages of infection. Along the same line, we are beginning to appreciate the master role of PCSK9, as a key regulator of cholesterol content. Some other pathways are carefully avoided by the pathogen allowing them to “silently” colonize the host without raising any red flag. This is the case of LCMV chronic infections that do not trigger any cellular unfolded protein response (UPR) pathway, the latter known to be activated by SKI-1/S1P mediated cleavage of ATF6 [156]. Overall, however, our current knowledge just gives us a glimpse over a very complex scenario where actors play roles in a plot not yet fully unraveled. More and more evidences, for example, start unveiling the contribution of PCs to the immune response: the same pathways that regulate lipid homeostasis – thought to be manipulated to favour the establishment of successful infections – are now shown to be a “wake-up call” for immunity [19, 157, 158]. In view of this situation, it is clear that more efforts are required to fill the gaps. The current SARS-CoV-2 pandemic further highlights that the scientific community is due for a shake-up. We need to invest more energies and resources to better understand pathogens and, of course, to develop effective drug treatments. In this context,

PCs represent ideal drug targets. First, by being proteases, these molecules possess defined substrate-binding pockets, which can be exploited as binding sites for pharmaceutical inhibitors [159]. In addition, the interference with PCs activity can be quantitatively measured by well established assays that allow rational lead optimization. Second, PCs are at the crossroad of multiple type of infections. Identification of powerful and safe PCs inhibitors may come in handy for current and newly arising pathogens, including SARS-CoV-2 and the emergence of a Furin-dependent influenza virus. The latter has been a matter of discussion during the last decade as a causative agent of a potential novel global pandemic [160, 161]. Likewise, targeting PCs would provide a powerful tool to modulate lipids, which are a “common denominator” of many enveloped viruses, e.g., flaviviruses, α -viruses, coronaviruses, filoviruses, retroviruses and more (**Table 1**).

Thus, PCs-targeted antivirals provide a great potential as general pandemic-preparedness tools. The advantage of targeting the host – i.e., PCs – consists in delivering a drug before the pandemic occurs and without knowing any details on the nature of the pathogen other than its dependence on these enzymes. Moreover, PCs fall into the “usual suspects” category, meaning they are popular and very often hijacked proteases and their involvement in future diseases is highly likely. In answer to those who claim toxic effects by PC-inhibition of critical host factors, we highlight that the drug administration should cover only a limited amount of time (few days), sufficiently to allow an appropriate immune response to the pathogen. Also, pharmaceutical companies manage to find drugs and dosing regimens against host proteins that people can tolerate. So, why should PCs antivirals be any different?

The present review clearly emphasized the seminal contribution of **Stefan Kunz** to our better understanding of the complex interplay between hemorrhagic fever viral surface glycoproteins folding and processing activation by SKI-1/S1P. The work of his team led the way towards a rational understanding of the structure-function of SKI-1/S1P, its zymogen activation steps and their effects on the processing of various arenaviruses that rely on this enzyme for their activation. The combination of his contributions to the monumental literature on the activation of enveloped viruses provided a distinct framework for future studies on the development of specific inhibitors or therapies against a multitude of infectious viruses. This is a solid base to build upon for our preparedness to counter the onslaught of present (e.g., COVID-19) and future pandemics that will surely arise because of the unrelenting interference and manipulation of wildlife and fauna by man and the ensuing loss of biodiversity.

Finally, two of us (AP and NGS) have had the privilege to work closely with Stefan Kunz, allowing us to appreciate his scientific intellect and curiosity. He will be fondly missed and remembered, and this review is a tribute and dedication to his memory.

Funding

This work was funded thanks to grants to NGS including a CIHR Foundation Scheme grant (# 148363), a Canada Chair in Precursor Proteolysis (# 950-231335) and a CHAMPS team grant (# HAL 157986) and to AP a EU Research Framework Programme H2020/Marie Skłodowska-Curie Actions grant #101024974.

Acknowledgements

The authors would like to acknowledge the expert secretarial help of Habiba Oueslati in the preparation of this manuscript.

Conflict of Interest and other Ethics Statements

None

References

1. Dobson, A. P.; Carper, E. R. Infectious Diseases and Human Population History: Throughout history the establishment of disease has been a side effect of the growth of civilization. *Bioscience* **1996**, *46*, 115-126.

2. Morens, D. M.; Folkers, G. K.; Fauci, A. S. Emerging infections: a perpetual challenge. *Lancet Infect. Dis.* **2008**, *8*, 710-9.

3. Cyranoski, D. Profile of a killer: the complex biology powering the coronavirus pandemic. *Nature* **2020**, *581*, 22-26.

4. Singh, R.; Kang, A.; Luo, X.; Jeyanathan, M.; Gillgrass, A.; Afkhami, S.; Xing, Z. COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development. *FASEB J.* **2021**, *35*, e21409.

5. Funk, C. D.; Laferrière, C.; Ardakani, A. Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective. *Viruses* **2021**, *13*.

6. Morens, D. M.; Fauci, A. S. Emerging Pandemic Diseases: How We Got to COVID-19. *Cell* **2020**, *182*, 1077-1092.

7. Owusu, I. A.; Quaye, O.; Passalacqua, K. D.; Wobus, C. E. Egress of non-enveloped enteric RNA viruses. *J. Gen. Virol.* **2021**.

8. Leroy, H.; Han, M.; Woottum, M.; Bracq, L.; Bouchet, J.; Xie, M.; Benichou, S. Virus-Mediated Cell-Cell Fusion. *Int. J. Mol. Sci.* **2020**, *21*, 9644.

9. Seidah, N. G.; Prat, A. The biology and therapeutic targeting of the proprotein convertases. *Nat Rev Drug Discov.* **2012**, *11*, 367-383.

10. Seidah, N. G.; Chretien, M. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. *Brain Res.* **1999**, *848*, 45-62.

11. Seidah, N. G.; Mowla, S. J.; Hamelin, J.; Mamarbachi, A. M.; Benjannet, S.; Toure, B. B.; Basak, A.; Munzer, J. S.; Marcinkiewicz, J.; Zhong, M.; Barale, J. C.; Lazure, C.; Murphy, R. A.; Chretien, M.; Marcinkiewicz, M. Mammalian subtilisin/kexin isozyme SKI-1: A widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. *Proc. Natl. Acad. Sci. U. S. A.* **1999**, *96*, 1321-1326.

12. Espenshade, P. J.; Cheng, D.; Goldstein, J. L.; Brown, M. S. Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-binding proteins. *J. Biol. Chem.* **1999**, *274*, 22795-22804.

13. Pullikotil, P.; Vincent, M.; Nichol, S. T.; Seidah, N. G. Development of protein-based inhibitors of the proprotein of convertase SKI-1/S1P: processing of SREBP-2, ATF6, and a viral glycoprotein. *J. Biol. Chem.* **2004**, *279*, 17338-17347.

14. Pasquato, A.; Pullikotil, P.; Asselin, M. C.; Vacatello, M.; Paolillo, L.; Ghezzi, F.; Basso, F.; Di Bello, C.; Dettin, M.; Seidah, N. G. The Proprotein Convertase SKI-1/S1P: in vitro analysis of lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors. *J. Biol. Chem.* **2006**, *281*, 23471-23481.

15. Seidah, N. G., Proprotein Convertases SKI-1/S1P and PCSK9. In *Handbook of the Biologically Active peptides*, Minamino, N.; Kastin, A., Eds. Academic Press: 2012; pp 1-8.

16. Seidah, N. G.; Benjannet, S.; Wickham, L.; Marcinkiewicz, J.; Jasmin, S. B.; Stifani, S.; Basak, A.; Prat, A.; Chretien, M. The secretory proprotein convertase neural apoptosis-

- regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. *Proc. Natl. Acad. Sci. U. S. A.* **2003**, *100*, 928-933.
17. Seidah, N. G.; Awan, Z.; Chretien, M.; Mbikay, M. PCSK9: A Key Modulator of Cardiovascular Health. *Circulation Research* **2014**, *114*, 1022-1036.
 18. Seidah, N. G.; Abifadel, M.; Prost, S.; Boileau, C.; Prat, A. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. *Pharmacol. Rev.* **2017**, *69*, 33-52.
 19. Liu, X.; Bao, X.; Hu, M.; Chang, H.; Jiao, M.; Cheng, J.; Xie, L.; Huang, Q.; Li, F.; Li, C. Y. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. *Nature* **2020**, *588*, 693-698.
 20. Thomas, G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. *Nature Reviews Molecular Cell Biology* **2002**, *3*, 753-766.
 21. Van de Ven, W. J.; Creemers, J. W.; Roebroek, A. J. Furin: the prototype mammalian subtilisin-like proprotein-processing enzyme. Endoproteolytic cleavage at paired basic residues of proproteins of the eukaryotic secretory pathway. *Enzyme* **1991**, *45*, 257-270.
 22. Moulard, M.; Decroly, E. Maturation of HIV envelope glycoprotein precursors by cellular endoproteases. *Biochim. Biophys. Acta* **2000**, *1469*, 121-132.
 23. Millet, J. K.; Whittaker, G. R. Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis. *Virus Res.* **2015**, *202*, 120-34.
 24. Braun, E.; Sauter, D. Furin-mediated protein processing in infectious diseases and cancer. *Clin Transl Immunology* **2019**, *8*, e1073.
 25. Izaguirre, G. The Proteolytic Regulation of Virus Cell Entry by Furin and Other Proprotein Convertases. *Viruses* **2019**, *11*.
 26. Le Coupanec, A.; Desforges, M.; Meessen-Pinard, M.; Dube, M.; Day, R.; Seidah, N. G.; Talbot, P. J. Cleavage of a Neuroinvasive Human Respiratory Virus Spike Glycoprotein by Proprotein Convertases Modulates Neurovirulence and Virus Spread within the Central Nervous System. *PLoS Pathog.* **2015**, *11*, e1005261.
 27. Tang, T.; Bidon, M.; Jaimes, J. A.; Whittaker, G. R.; Daniel, S. Coronavirus membrane fusion mechanism offers as a potential target for antiviral development. *Antiviral Res.* **2020**, 104792.
 28. Seidah, N. G. The proprotein convertases, 20 years later. *Methods Mol. Biol.* **2011**, *768*, 23-57.
 29. Hallenberger, S.; Bosch, V.; Angliker, H.; Shaw, E.; Klenk, H. D.; Garten, W. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. *Nature* **1992**, *360*, 358-361.
 30. Li, Z.; Sergel, T.; Razvi, E.; Morrison, T. Effect of cleavage mutants on syncytium formation directed by the wild-type fusion protein of Newcastle disease virus. *J. Virol.* **1998**, *72*, 3789-95.
 31. Walker, J. A.; Molloy, S. S.; Thomas, G.; Sakaguchi, T.; Yoshida, T.; Chambers, T. M.; Kawaoka, Y. Sequence specificity of furin, a proprotein-processing endoprotease, for the hemagglutinin of a virulent avian influenza virus. *J. Virol.* **1994**, *68*, 1213-1218.
 32. Gao, P.; Watanabe, S.; Ito, T.; Goto, H.; Wells, K.; McGregor, M.; Cooley, A. J.; Kawaoka, Y. Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. *J. Virol.* **1999**, *73*, 3184-9.
 33. Basak, A.; Zhong, M.; Munzer, J. S.; Chretien, M.; Seidah, N. G. Implication of the proprotein convertases furin, PC5 and PC7 in the cleavage of surface glycoproteins of

- Hong Kong, Ebola and respiratory syncytial viruses: a comparative analysis with fluorogenic peptides. *Biochem. J.* **2001**, *353*, 537-545.
34. Böttcher, E.; Matrosovich, T.; Beyerle, M.; Klenk, H. D.; Garten, W.; Matrosovich, M. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. *J. Virol.* **2006**, *80*, 9896-8.
 35. Murza, A.; Dion, S. P.; Boudreault, P. L.; Désilets, A.; Leduc, R.; Marsault, É. Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract - A review of patent literature. *Expert Opin. Ther. Pat.* **2020**, *30*, 807-824.
 36. Sachan, V.; Lodge, R.; Mihara, K.; Hamelin, J.; Power, C.; Gelman, B. B.; Hollenberg, M. D.; Cohen É, A.; Seidah, N. G. HIV-induced neuroinflammation: impact of PAR1 and PAR2 processing by Furin. *Cell Death Differentiation* **2019**, *26*, 1942-1954.
 37. Ohuchi, M.; Orlich, M.; Ohuchi, R.; Simpson, B. E.; Garten, W.; Klenk, H. D.; Rott, R. Mutations at the cleavage site of the hemagglutinin alter the pathogenicity of influenza virus A/chick/Penn/83 (H5N2). *Virology* **1989**, *168*, 274-80.
 38. Gu, M.; Rappaport, J.; Leppla, S. H. Furin is important but not essential for the proteolytic maturation of gp160 of HIV-1. *FEBS Lett.* **1995**, *365*, 95-97.
 39. Aerts, L.; Hamelin, M. E.; Rh, aume, C.; Lavigne, S.; Couture, C.; Kim, W.; Susan-Resiga, D.; Prat, A.; Seidah, N. G.; Vergnolle, N.; Boivin, G. Modulation of protease activated receptor 1 influences human metapneumovirus disease severity in a mouse model. *PLoS One* **2013**, *8*, e72529.
 40. Kim, W.; Zekas, E.; Lodge, R.; Susan-Resiga, D.; Marcinkiewicz, E.; Essalmani, R.; Mihara, K.; Ramachandran, R.; Asahchop, E.; Gelman, B.; Cohen, E. A.; Power, C.; Hollenberg, M. D.; Seidah, N. G. Neuroinflammation-Induced Interactions between Protease-Activated Receptor 1 and Proprotein Convertases in HIV-Associated Neurocognitive Disorder. *Mol. Cell Biol.* **2015**, *35*, 3684-3700.
 41. Braun, E.; Hotter, D.; Koepke, L.; Zech, F.; Groß, R.; Sparrer, K. M. J.; Müller, J. A.; Pfaller, C. K.; Heusinger, E.; Wombacher, R.; Sutter, K.; Dittmer, U.; Winkler, M.; Simmons, G.; Jakobsen, M. R.; Conzelmann, K. K.; Pöhlmann, S.; Münch, J.; Fackler, O. T.; Kirchhoff, F.; Sauter, D. Guanylate-Binding Proteins 2 and 5 Exert Broad Antiviral Activity by Inhibiting Furin-Mediated Processing of Viral Envelope Proteins. *Cell Rep* **2019**, *27*, 2092-2104.e10.
 42. Volchkov, V. E.; Feldmann, H.; Volchkova, V. A.; Klenk, H. D. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. *Proc. Natl. Acad. Sci. U. S. A.* **1998**, *95*, 5762-5767.
 43. Neumann, G.; Feldmann, H.; Watanabe, S.; Lukashevich, I.; Kawaoka, Y. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. *J. Virol.* **2002**, *76*, 406-10.
 44. Neumann, G.; Geisbert, T. W.; Ebihara, H.; Geisbert, J. B.; Daddario-DiCaprio, K. M.; Feldmann, H.; Kawaoka, Y. Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates. *J. Virol.* **2007**, *81*, 2995-8.
 45. Wang, B.; Wang, Y.; Frabutt, D. A.; Zhang, X.; Yao, X.; Hu, D.; Zhang, Z.; Liu, C.; Zheng, S.; Xiang, S. H.; Zheng, Y. H. Mechanistic understanding of N-glycosylation in Ebola virus glycoprotein maturation and function. *J. Biol. Chem.* **2017**, *292*, 5860-5870.
 46. Yu, C.; Li, S.; Zhang, X.; Khan, I.; Ahmad, I.; Zhou, Y.; Li, S.; Shi, J.; Wang, Y.; Zheng, Y. H. MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus

- Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation. *mBio* **2020**, *11*.
47. Stadler, K.; Allison, S. L.; Schlich, J.; Heinz, F. X. Proteolytic activation of tick-borne encephalitis virus by furin. *J. Virol.* **1997**, *71*, 8475-81.
 48. Zybert, I. A.; van der Ende-Metselaar, H.; Wilschut, J.; Smit, J. M. Functional importance of dengue virus maturation: infectious properties of immature virions. *J. Gen. Virol.* **2008**, *89*, 3047-3051.
 49. da Silva Voorham, J. M.; Rodenhuis-Zybert, I. A.; Ayala Nuñez, N. V.; Colpitts, T. M.; van der Ende-Metselaar, H.; Fikrig, E.; Diamond, M. S.; Wilschut, J.; Smit, J. M. Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2. *PLoS One* **2012**, *7*, e29957.
 50. Rodenhuis-Zybert, I. A.; van der Schaar, H. M.; da Silva Voorham, J. M.; van der Ende-Metselaar, H.; Lei, H. Y.; Wilschut, J.; Smit, J. M. Immature dengue virus: a veiled pathogen? *PLoS Pathog.* **2010**, *6*, e1000718.
 51. VanBlargan, L. A.; Errico, J. M.; Kafai, N. M.; Burgomaster, K. E.; Jethva, P. N.; Broeckel, R. M.; Meade-White, K.; Nelson, C. A.; Himansu, S.; Wang, D.; Handley, S. A.; Gross, M. L.; Best, S. M.; Pierson, T. C.; Fremont, D. H.; Diamond, M. S. Broadly neutralizing monoclonal antibodies protect against multiple tick-borne flaviviruses. *J. Exp. Med.* **2021**, *218*.
 52. Ozden, S.; Lucas-Hourani, M.; Ceccaldi, P. E.; Basak, A.; Valentine, M.; Benjannet, S.; Hamelin, J.; Jacob, Y.; Mamchaoui, K.; Mouly, V.; Despres, P.; Gessain, A.; Butler-Browne, G.; Chretien, M.; Tangy, F.; Vidalain, P. O.; Seidah, N. G. Inhibition of Chikungunya Virus Infection in Cultured Human Muscle Cells by Furin Inhibitors: Impairment of the maturation of the E2 surface glycoprotein. *J. Biol. Chem.* **2008**, *283*, 21899-21908.
 53. Kropp, K. A.; Srivaratharajan, S.; Ritter, B.; Yu, P.; Krooss, S.; Polten, F.; Pich, A.; Alcami, A.; Viejo-Borbolla, A. Identification of the Cleavage Domain within Glycoprotein G of Herpes Simplex Virus Type 2. *Viruses* **2020**, *12*.
 54. Oliver, S. L.; Sommer, M.; Zerboni, L.; Rajamani, J.; Grose, C.; Arvin, A. M. Mutagenesis of varicella-zoster virus glycoprotein B: putative fusion loop residues are essential for viral replication, and the furin cleavage motif contributes to pathogenesis in skin tissue in vivo. *J. Virol.* **2009**, *83*, 7495-506.
 55. Emerman, M.; Malim, M. H. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. *Science* **1998**, *280*, 1880-4.
 56. Wallet, C.; Rohr, O.; Schwartz, C. Evolution of a concept: From accessory protein to key virulence factor, the case of HIV-1 Vpr. *Biochem. Pharmacol.* **2020**, *180*, 114128.
 57. Mayer, G.; Hamelin, J.; Asselin, M. C.; Pasquato, A.; Marcinkiewicz, E.; Tang, M.; Tabibzadeh, S.; Seidah, N. G. The regulated cell surface zymogen activation of the proprotein convertase PC5A directs the processing of its secretory substrates. *J. Biol. Chem.* **2008**, *283*, 2373-2384.
 58. Xiao, Y.; Chen, G.; Richard, J.; Rougeau, N.; Li, H.; Seidah, N. G.; Cohen, E. A. Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases. *Virology* **2008**, *372*, 384-397.
 59. Bosch, B. J.; van der, Z. R.; de Haan, C. A.; Rottier, P. J. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. *J. Virol.* **2003**, *77*, 8801-8811.

- 948 60. de Wit, E.; van Doremalen, N.; Falzarano, D.; Munster, V. J. SARS and MERS: recent
949 insights into emerging coronaviruses. *Nat. Rev. Microbiol.* **2016**, *14*, 523-34.
- 950 61. Li, W.; Moore, M. J.; Vasilieva, N.; Sui, J.; Wong, S. K.; Berne, M. A.; Somasundaran,
951 M.; Sullivan, J. L.; Luzuriaga, K.; Greenough, T. C.; Choe, H.; Farzan, M. Angiotensin-
952 converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* **2003**,
953 *426*, 450-454.
- 954 62. Lu, G.; Hu, Y.; Wang, Q.; Qi, J.; Gao, F.; Li, Y.; Zhang, Y.; Zhang, W.; Yuan, Y.; Bao,
955 J.; Zhang, B.; Shi, Y.; Yan, J.; Gao, G. F. Molecular basis of binding between novel
956 human coronavirus MERS-CoV and its receptor CD26. *Nature* **2013**, *500*, 227-31.
- 957 63. Belouzard, S.; Madu, I.; Whittaker, G. R. Elastase-mediated activation of the severe acute
958 respiratory syndrome coronavirus spike protein at discrete sites within the S2 domain. *J.*
959 *Biol. Chem.* **2010**, *285*, 22758-63.
- 960 64. Belouzard, S.; Millet, J. K.; Licitra, B. N.; Whittaker, G. R. Mechanisms of coronavirus
961 cell entry mediated by the viral spike protein. *Viruses* **2012**, *4*, 1011-33.
- 962 65. Shirato, K.; Kawase, M.; Matsuyama, S. Middle East respiratory syndrome coronavirus
963 infection mediated by the transmembrane serine protease TMPRSS2. *J. Virol.* **2013**, *87*,
964 12552-61.
- 965 66. Kleine-Weber, H.; Elzayat, M. T.; Hoffmann, M.; Pöhlmann, S. Functional analysis of
966 potential cleavage sites in the MERS-coronavirus spike protein. *Sci. Rep.* **2018**, *8*, 16597.
- 967 67. Hörnich, B. F.; Großkopf, A. K.; Schlagowski, S.; Tenbusch, M.; Kleine-Weber, H.;
968 Neipel, F.; Stahl-Hennig, C.; Hahn, A. S. SARS-CoV-2 and SARS-CoV spike-mediated
969 cell-cell fusion differ in the requirements for receptor expression and proteolytic
970 activation. *J. Virol.* **2021**.
- 971 68. Coutard, B.; Valle, C.; de Lamballerie, X.; Canard, B.; Seidah, N. G.; Decroly, E. The
972 spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site
973 absent in CoV of the same clade. *Antiviral Res.* **2020**, *176*, 104742.
- 974 69. Bollavaram, K.; Leeman, T. H.; Lee, M. W.; Kulkarni, A.; Upshaw, S. G.; Yang, J.; Song,
975 H.; Platt, M. O. Multiple Sites on SARS-CoV-2 Spike Protein are Susceptible to
976 Proteolysis by Cathepsins B, K, L, S, and V. *Protein Sci.* **2021**.
- 977 70. Kawase, M.; Shirato, K.; van der Hoek, L.; Taguchi, F.; Matsuyama, S. Simultaneous
978 treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors
979 prevents severe acute respiratory syndrome coronavirus entry. *J. Virol.* **2012**, *86*, 6537-
980 45.
- 981 71. Nimishakavi, S.; Raymond, W. W.; Gruenert, D. C.; Caughey, G. H. Divergent Inhibitor
982 Susceptibility among Airway Lumen-Accessible Tryptic Proteases. *PLoS One* **2015**, *10*,
983 e0141169.
- 984 72. Essalmani, R.; Jain, J.; Susan-Resiga, D.; Andréo, U.; Evagelidis, A.; Derbali, R. M.;
985 Huynh, D. N.; Dallaire, F.; Laporte, M.; Delpal, A.; Sutto-Ortiz, P.; Coutard, B.; Mapa,
986 C.; Wilcoxon, K.; Decroly, É.; Pham, T. N.; Cohen, É. A.; Seidah, N. G. Furin cleaves
987 SARS-CoV-2 spike-glycoprotein at S1/S2 and S2' for viral fusion/entry: indirect role of
988 TMPRSS2. *bioRxiv* **2020**, 2020.12.18.423106.
- 989 73. Raghuvamsi, P. V.; Tulsian, N. K.; Samsudin, F.; Qian, X.; Purushotorman, K.; Yue, G.;
990 Kozma, M. M.; Hwa, W. Y.; Lescar, J.; Bond, P. J.; MacAry, P. A.; Anand, G. S. SARS-
991 CoV-2 S protein:ACE2 interaction reveals novel allosteric targets. *Elife* **2021**, *10*.

- 992 74. Tang, T.; Jaimes, J. A.; Bidon, M. K.; Straus, M. R.; Daniel, S.; Whittaker, G. R.
993 Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of
994 Proteases beyond Furin. *ACS Infect Dis* **2021**.
- 995 75. Vincent, M. J.; Bergeron, E.; Benjannet, S.; Erickson, B. R.; Rollin, P. E.; Ksiazek, T.
996 G.; Seidah, N. G.; Nichol, S. T. Chloroquine is a potent inhibitor of SARS coronavirus
997 infection and spread. *Viol. J* **2005**, 2, 69.
- 998 76. Hache, G.; Rolain, J. M.; Gautret, P.; Deharo, J. C.; Brouqui, P.; Raoult, D.; Honoré, S.
999 Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for
1000 COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
1001 *Microb. Drug Resist.* **2021**, 27, 281-290.
- 1002 77. Leung, K.; Shum, M. H.; Leung, G. M.; Lam, T. T.; Wu, J. T. Early transmissibility
1003 assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom,
1004 October to November 2020. *Euro Surveill.* **2021**, 26.
- 1005 78. Tegally, H.; Wilkinson, E.; Giovanetti, M.; Iranzadeh, A.; Fonseca, V.; Giandhari, J.;
1006 Doolabh, D.; Pillay, S.; San, E. J.; Msomi, N.; Mlisana, K.; von Gottberg, A.; Walaza,
1007 S.; Allam, M.; Ismail, A.; Mohale, T.; Glass, A. J.; Engelbrecht, S.; Van Zyl, G.; Preiser,
1008 W.; Petruccione, F.; Sigal, A.; Hardie, D.; Marais, G.; Hsiao, M.; Korsman, S.; Davies,
1009 M.-A.; Tyers, L.; Mudau, I.; York, D.; Maslo, C.; Goedhals, D.; Abrahams, S.; Laguda-
1010 Akingba, O.; Alisoltani-Dehkordi, A.; Godzik, A.; Wibmer, C. K.; Sewell, B. T.;
1011 Lourenço, J.; Alcantara, L. C. J.; Pond, S. L. K.; Weaver, S.; Martin, D.; Lessells, R. J.;
1012 Bhiman, J. N.; Williamson, C.; de Oliveira, T. Emergence and rapid spread of a new
1013 severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with
1014 multiple spike mutations in South Africa. *medRxiv* **2020**, 2020.12.21.20248640.
- 1015 79. Fujino, T.; Nomoto, H.; Kutsuna, S.; Ujiie, M.; Suzuki, T.; Sato, R.; Fujimoto, T.;
1016 Kuroda, M.; Wakita, T.; Ohmagari, N. Novel SARS-CoV-2 Variant Identified in
1017 Travelers from Brazil to Japan. *Emerg. Infect. Dis.* **2021**, 27.
- 1018 80. Zahradník, J.; Marciano, S.; Shemesh, M.; Zoler, E.; Chiaravalli, J.; Meyer, B.; Dym, O.;
1019 Elad, N.; Schreiber, G. SARS-CoV-2 RBD in vitro evolution follows
1020 contagious mutation spread, yet generates an able infection inhibitor. *bioRxiv* **2021**,
1021 2021.01.06.425392.
- 1022 81. Wang, P.; Nair, M. S.; Liu, L.; Iketani, S.; Luo, Y.; Guo, Y.; Wang, M.; Yu, J.; Zhang,
1023 B.; Kwong, P. D.; Graham, B. S.; Mascola, J. R.; Chang, J. Y.; Yin, M. T.; Sobieszczyk,
1024 M.; Kyratsous, C. A.; Shapiro, L.; Sheng, Z.; Huang, Y.; Ho, D. D. Antibody Resistance
1025 of SARS-CoV-2 Variants B.1.351 and B.1.1.7. *Nature* **2021**.
- 1026 82. Chen, R. E.; Zhang, X.; Case, J. B.; Winkler, E. S.; Liu, Y.; VanBlargan, L. A.; Liu, J.;
1027 Errico, J. M.; Xie, X.; Suryadevara, N.; Gilchuk, P.; Zost, S. J.; Tahan, S.; Droit, L.;
1028 Turner, J. S.; Kim, W.; Schmitz, A. J.; Thapa, M.; Wang, D.; Boon, A. C. M.; Presti, R.
1029 M.; O'Halloran, J. A.; Kim, A. H. J.; Deepak, P.; Pinto, D.; Fremont, D. H.; Crowe, J. E.,
1030 Jr.; Corti, D.; Virgin, H. W.; Ellebedy, A. H.; Shi, P. Y.; Diamond, M. S. Resistance of
1031 SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal
1032 antibodies. *Nat. Med.* **2021**.
- 1033 83. Morens, D. M.; Fauci, A. S. Emerging Pandemic Diseases: How We Got to COVID-19.
1034 *Cell* **2020**, 183, 837.
- 1035 84. Benjannet, S.; Rhainds, D.; Essalmani, R.; Mayne, J.; Wickham, L.; Jin, W.; Asselin, M.
1036 C.; Hamelin, J.; Varret, M.; Allard, D.; Trillard, M.; Abifadel, M.; Tebon, A.; Attie, A.
1037 D.; Rader, D. J.; Boileau, C.; Brissette, L.; Chretien, M.; Prat, A.; Seidah, N. G. NARC-

- 1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. *J. Biol. Chem.* **2004**, *279*, 48865-48875.
85. Li, J.; Tumanut, C.; Gavigan, J. A.; Huang, W. J.; Hampton, E. N.; Tumanut, R.; Suen, K. F.; Trauger, J. W.; Spraggon, G.; Lesley, S. A.; Liao, G.; Yowe, D.; Harris, J. L. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. *Biochem. J.* **2007**, *406*, 203-7.
86. Abifadel, M.; Varret, M.; Rabes, J. P.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.; Wickham, L.; Erlich, D.; Derre, A.; Villeger, L.; Farnier, M.; Beucler, I.; Bruckert, E.; Chambaz, J.; Chanu, B.; Lecerf, J. M.; Luc, G.; Moulin, P.; Weissenbach, J.; Prat, A.; Krempf, M.; Junien, C.; Seidah, N. G.; Boileau, C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat. Genet.* **2003**, *34*, 154-156.
87. Cohen, J.; Pertsemlidis, A.; Kotowski, I. K.; Graham, R.; Garcia, C. K.; Hobbs, H. H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. *Nat. Genet.* **2005**, *37*, 161.
88. Maxwell, K. N.; Breslow, J. L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. *Proc. Natl. Acad. Sci. U. S. A.* **2004**, *101*, 7100-7105.
89. Park, S. W.; Moon, Y. A.; Horton, J. D. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. *J. Biol. Chem.* **2004**, *279*, 50630-50638.
90. Syed, G. H.; Tang, H.; Khan, M.; Hassanein, T.; Liu, J.; Siddiqui, A. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. *J. Virol.* **2014**, *88*, 2519-2529.
91. Li, Z.; Liu, Q. Hepatitis C virus regulates proprotein convertase subtilisin/kexin type 9 promoter activity. *Biochem Biophys Res Commun* **2018**, *496*, 1229-1235.
92. Ramanathan, A.; Gusarova, V.; Stahl, N.; Gurnett-Bander, A.; Kyratsous, C. A. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes. *PLoS One* **2016**, *11*, e0154498.
93. Bridge, S. H.; Sheridan, D. A.; Felmlee, D. J.; Crossey, M. M.; Fenwick, F. I.; Lanyon, C. V.; Dubuc, G.; Seidah, N. G.; Davignon, J.; Thomas, H. C.; Taylor-Robinson, S. D.; Toms, G. L.; Neely, R. D.; Bassendine, M. F. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. *J. Hepatol.* **2014**, *62*, 763-770.
94. Fasolato, S.; Pigozzo, S.; Pontisso, P.; Angeli, P.; Ruscica, M.; Savarino, E.; De Martin, S.; Lupo, M. G.; Ferri, N. PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. *J Clin Med* **2020**, *9*.
95. Bhatt, S.; Gething, P. W.; Brady, O. J.; Messina, J. P.; Farlow, A. W.; Moyes, C. L.; Drake, J. M.; Brownstein, J. S.; Hoen, A. G.; Sankoh, O.; Myers, M. F.; George, D. B.; Jaenisch, T.; Wint, G. R.; Simmons, C. P.; Scott, T. W.; Farrar, J. J.; Hay, S. I. The global distribution and burden of dengue. *Nature* **2013**, *496*, 504-7.
96. Junjhon, J.; Lausumpao, M.; Supasa, S.; Noisakran, S.; Songjaeng, A.; Saraithong, P.; Chaichoun, K.; Utaipat, U.; Keelapang, P.; Kanjanahaluethai, A.; Puttikhunt, C.; Kasinrerk, W.; Malasit, P.; Sittisombut, N. Differential modulation of prM cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfuran consensus positions of the dengue virus pr-M junction. *J. Virol.* **2008**, *82*, 10776-91.

- 1084 97. Rana, J.; Slon Campos, J. L.; Poggianella, M.; Burrone, O. R. Dengue virus capsid anchor
1085 modulates the efficiency of polyprotein processing and assembly of viral particles. *J.*
1086 *Gen. Virol.* **2019**, *100*, 1663-1673.
- 1087 98. Gan, E. S.; Tan, H. C.; Le, D. H. T.; Huynh, T. T.; Wills, B.; Seidah, N. G.; Ooi, E. E.;
1088 Yacoub, S. Dengue virus induces PCSK9 expression to alter antiviral responses and
1089 disease outcomes. *J. Clin. Invest.* **2020**, *130*, 5223-5234.
- 1090 99. Sakai, J.; Rawson, R. B.; Espenshade, P. J.; Cheng, D.; Seegmiller, A. C.; Goldstein, J.
1091 L.; Brown, M. S. Molecular identification of the sterol-regulated luminal protease that
1092 cleaves SREBPs and controls lipid composition of animal cells. *Molecular of the Cell*
1093 **1998**, *2*, 505-514.
- 1094 100. da Palma, J. R.; Burri, D. J.; Oppliger, J.; Salamina, M.; Cendron, L.; de Laureto, P. P.;
1095 Seidah, N. G.; Kunz, S.; Pasquato, A. Zymogen activation and subcellular activity of
1096 subtilisin kexin isozyme 1/site 1 protease. *J. Biol. Chem.* **2014**, *289*, 35743-35756.
- 1097 101. Tagliabracci, V. S.; Wiley, S. E.; Guo, X.; Kinch, L. N.; Durrant, E.; Wen, J.; Xiao, J.;
1098 Cui, J.; Nguyen, K. B.; Engel, J. L.; Coon, J. J.; Grishin, N.; Pinna, L. A.; Pagliarini, D.
1099 J.; Dixon, J. E. A Single Kinase Generates the Majority of the Secreted
1100 Phosphoproteome. *Cell* **2015**, *161*, 1619-1632.
- 1101 102. Marschner, K.; Kollmann, K.; Schweizer, M.; Bräulke, T.; Pohl, S. A key enzyme in the
1102 biogenesis of lysosomes is a protease that regulates cholesterol metabolism. *Science*
1103 **2011**, *333*, 87-90.
- 1104 103. Nakagawa, T.; Suzuki-Nakagawa, C.; Watanabe, A.; Asami, E.; Matsumoto, M.;
1105 Nakano, M.; Ebihara, A.; Uddin, M. N.; Suzuki, F. Site-1 protease is required for the
1106 generation of soluble (pro)renin receptor. *J. Biochem.* **2017**, *161*, 369-379.
- 1107 104. Kondo, Y.; Fu, J.; Wang, H.; Hoover, C.; McDaniel, J. M.; Steet, R.; Patra, D.; Song, J.;
1108 Pollard, L.; Cathey, S.; Yago, T.; Wiley, G.; Macwana, S.; Guthridge, J.; McGee, S.; Li,
1109 S.; Griffin, C.; Furukawa, K.; James, J. A.; Ruan, C.; McEver, R. P.; Wierenga, K. J.;
1110 Gaffney, P. M.; Xia, L. Site-1 protease deficiency causes human skeletal dysplasia due
1111 to defective inter-organelle protein trafficking. *JCI Insight* **2018**, *3*.
- 1112 105. Meyer, R.; Elbracht, M.; Opladen, T.; Eggermann, T. Patient with an autosomal-recessive
1113 MBTPS1-linked phenotype and clinical features of Silver-Russell syndrome. *Am. J. Med.*
1114 *Genet. A* **2020**, *182*, 2727-2730.
- 1115 106. Lenz, O.; ter Meulen, J.; Klenk, H. D.; Seidah, N. G.; Garten, W. The Lassa virus
1116 glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. *Proc.*
1117 *Natl. Acad. Sci. U. S. A.* **2001**, *98*, 12701-12705.
- 1118 107. Burri, D. J.; Pasqual, G.; Rochat, C.; Seidah, N. G.; Pasquato, A.; Kunz, S. Molecular
1119 characterization of the processing of arenavirus envelope glycoprotein precursors by
1120 subtilisin kexin isozyme-1/site-1 protease. *J Virol.* **2012**, *86*, 4935-4946.
- 1121 108. Burri, D. J.; da Palma, J. R.; Seidah, N. G.; Zanotti, G.; Cendron, L.; Pasquato, A.; Kunz,
1122 S. Differential recognition of Old World and New World arenavirus envelope
1123 glycoproteins by subtilisin kexin isozyme 1 (SKI-1)/site 1 protease (S1P). *J. Virol.* **2013**,
1124 *87*, 6406-14.
- 1125 109. McCormick, J. B.; Webb, P. A.; Krebs, J. W.; Johnson, K. M.; Smith, E. S. A prospective
1126 study of the epidemiology and ecology of Lassa fever. *J. Infect. Dis.* **1987**, *155*, 437-44.
- 1127 110. da Palma, J. R.; Cendron, L.; Seidah, N. G.; Pasquato, A.; Kunz, S. Mechanism of Folding
1128 and Activation of Subtilisin Kexin Isozyme-1 (SKI-1)/Site-1 Protease (S1P). *J. Biol.*
1129 *Chem.* **2016**, *291*, 2055-66.

- 1130 111. Flatz, L.; Rieger, T.; Merkler, D.; Bergthaler, A.; Regen, T.; Schedensack, M.; Bestmann,
1131 L.; Verschoor, A.; Kreutzfeldt, M.; Brück, W.; Hanisch, U. K.; Günther, S.; Pinschewer,
1132 D. D. T cell-dependence of Lassa fever pathogenesis. *PLoS Pathog.* **2010**, *6*, e1000836.
- 1133 112. Seidah, N. G.; Prat, A.; Pirillo, A.; Catapano, A. L.; Norata, G. D. Novel strategies to
1134 target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
1135 *Cardiovasc. Res.* **2019**, *115*, 510-518.
- 1136 113. Hatch, S.; Mathew, A.; Rothman, A. Dengue vaccine: opportunities and challenges.
1137 *IDrugs* **2008**, *11*, 42-5.
- 1138 114. Beyer, W. R.; Popplau, D.; Garten, W.; Von Laer, D.; Lenz, O. Endoproteolytic
1139 Processing of the Lymphocytic Choriomeningitis Virus Glycoprotein by the Subtilase
1140 SKI-1/S1P. *J. Virol.* **2003**, *77*, 2866-2872.
- 1141 115. Burri, D. J.; Pasqual, G.; Rochat, C.; Seidah, N. G.; Pasquato, A.; Kunz, S. Molecular
1142 characterization of the processing of arenavirus envelope glycoprotein precursors by
1143 subtilisin kexin isozyme-1/site-1 protease. *J. Virol.* **2012**, *86*, 4935-4946.
- 1144 116. Kunz, S.; Edelmann, K. H.; de la Torre, J. C.; Gorney, R.; Oldstone, M. B. Mechanisms
1145 for lymphocytic choriomeningitis virus glycoprotein cleavage, transport, and
1146 incorporation into virions. *Virology* **2003**, *314*, 168-178.
- 1147 117. Wright, K. E.; Spiro, R. C.; Burns, J. W.; Buchmeier, M. J. Post-translational processing
1148 of the glycoproteins of lymphocytic choriomeningitis virus. *Virology* **1990**, *177*, 175-83.
- 1149 118. Briese, T.; Paweska, J. T.; McMullan, L. K.; Hutchison, S. K.; Street, C.; Palacios, G.;
1150 Khristova, M. L.; Weyer, J.; Swanepoel, R.; Egholm, M.; Nichol, S. T.; Lipkin, W. I.
1151 Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated
1152 arenavirus from southern Africa. *PLoS Pathog.* **2009**, *5*, e1000455.
- 1153 119. Oppliger, J.; da Palma, J. R.; Burri, D. J.; Bergeron, E.; Khatib, A. M.; Spiropoulou, C.
1154 F.; Pasquato, A.; Kunz, S. A Molecular Sensor To Characterize Arenavirus Envelope
1155 Glycoprotein Cleavage by Subtilisin Kexin Isozyme 1/Site 1 Protease. *J. Virol.* **2016**, *90*,
1156 705-14.
- 1157 120. Grant, A.; Seregin, A.; Huang, C.; Kolokoltsova, O.; Brasier, A.; Peters, C.; Paessler, S.
1158 Junín virus pathogenesis and virus replication. *Viruses* **2012**, *4*, 2317-39.
- 1159 121. Candurra, N. A.; Damonte, E. B. Effect of inhibitors of the intracellular exocytic pathway
1160 on glycoprotein processing and maturation of Junin virus. *Arch. Virol.* **1997**, *142*, 2179-
1161 93.
- 1162 122. Toure, B. B.; Munzer, J. S.; Basak, A.; Benjannet, S.; Rochemont, J.; Lazure, C.;
1163 Chretien, M.; Seidah, N. G. Biosynthesis and enzymatic characterization of human SKI-
1164 1/S1P and the processing of its inhibitory prosegment. *J. Biol. Chem.* **2000**, *275*, 2349-
1165 2358.
- 1166 123. Pasquato, A.; Burri, D. J.; Traba, E. G.; Hanna-El-Daher, L.; Seidah, N. G.; Kunz, S.
1167 Arenavirus envelope glycoproteins mimic autoprocessing sites of the cellular proprotein
1168 convertase subtilisin kexin isozyme-1/site-1 protease. *Virology* **2011**.
- 1169 124. Pasqual, G.; Burri, D. J.; Pasquato, A.; de la Torre, J. C.; Kunz, S. Role of the host cell's
1170 unfolded protein response in arenavirus infection. *J. Virol.* **2011**, *85*, 1662-70.
- 1171 125. Manning, J. T.; Yun, N. E.; Seregin, A. V.; Koma, T.; Sattler, R. A.; Ezeomah, C.; Huang,
1172 C.; de la Torre, J. C.; Paessler, S. The Glycoprotein of the Live-Attenuated Junin Virus
1173 Vaccine Strain Induces Endoplasmic Reticulum Stress and Forms Aggregates prior to
1174 Degradation in the Lysosome. *J. Virol.* **2020**, *94*.

- 1175 126. Popkin, D. L.; Teijaro, J. R.; Sullivan, B. M.; Urata, S.; Rutschmann, S.; de la Torre, J.
1176 C.; Kunz, S.; Beutler, B.; Oldstone, M. Hypomorphic mutation in the site-1 protease
1177 Mbtsp1 endows resistance to persistent viral infection in a cell-specific manner. *Cell Host*
1178 *Microbe* **2011**, *9*, 212-222.
- 1179 127. Burri, D. J.; da Palma, J. R.; Kunz, S.; Pasquato, A. Envelope glycoprotein of
1180 arenaviruses. *Viruses* **2012**, *4*, 2162-81.
- 1181 128. Maisa, A.; Stroher, U.; Klenk, H. D.; Garten, W.; Strecker, T. Inhibition of Lassa virus
1182 glycoprotein cleavage and multicycle replication by site 1 protease-adapted alpha(1)-
1183 antitrypsin variants. *PLoS. Negl. Trop. Dis.* **2009**, *3*, e446.
- 1184 129. Basak, A.; Goswami, M.; Rajkumar, A.; Mitra, T.; Majumdar, S.; O'Reilly, P.; Bdour, H.
1185 M.; Trudeau, V. L.; Basak, A. Enediynyl peptides and iso-coumarinyl methyl sulfones as
1186 inhibitors of proprotein convertases PCSK8/SKI-1/S1P and PCSK4/PC4: Design,
1187 synthesis and biological evaluations. *Bioorg Med Chem Lett* **2015**, *25*, 2225-37.
- 1188 130. Rojek, J. M.; Pasqual, G.; Sanchez, A. B.; Nguyen, N. T.; de la Torre, J. C.; Kunz, S.
1189 Targeting the proteolytic processing of the viral glycoprotein precursor is a promising
1190 novel antiviral strategy against arenaviruses. *J Virol.* **2010**, *84*, 573-584.
- 1191 131. Hay, B. A.; Abrams, B.; Zumbunn, A. Y.; Valentine, J. J.; Warren, L. C.; Petras, S. F.;
1192 Shelly, L. D.; Xia, A.; Varghese, A. H.; Hawkins, J. L.; Van Camp, J. A.; Robbins, M.
1193 D.; Landschulz, K.; Harwood, H. J., Jr. Aminopyrrolidineamide inhibitors of site-1
1194 protease. *Bioorganic and Medicinal Chemistry Letters* **2007**, *17*, 4411-4414.
- 1195 132. Hawkins, J. L.; Robbins, M. D.; Warren, L. C.; Xia, D.; Petras, S. F.; Valentine, J. J.;
1196 Varghese, A. H.; Wang, I. K.; Subashi, T. A.; Shelly, L. D.; Hay, B. A.; Landschulz, K.
1197 T.; Geoghegan, K. F.; Harwood, H. J., Jr. Pharmacologic inhibition of site 1 protease
1198 activity inhibits sterol regulatory element-binding protein processing and reduces
1199 lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental
1200 animals. *Journal of Pharmacology and Experimental Therapeutics* **2008**, *326*, 801-808.
- 1201 133. Urata, S.; Yun, N.; Pasquato, A.; Paessler, S.; Kunz, S.; de la Torre, J. C. Antiviral activity
1202 of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1
1203 protease. *J Virol.* **2011**, *85*, 795-803.
- 1204 134. Pasquato, A.; Rochat, C.; Burri, D. J.; Pasqual, G.; la Torre, J. C.; Kunz, S. Evaluation of
1205 the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-
1206 429242. *Virology* **2012**, *423*, 14-22.
- 1207 135. Vincent, M. J.; Sanchez, A. J.; Erickson, B. R.; Basak, A.; Chretien, M.; Seidah, N. G.;
1208 Nichol, S. T. Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic
1209 processing by subtilase SKI-1. *J. Virol.* **2003**, *77*, 8640-8649.
- 1210 136. Bergeron, E.; Vincent, M. J.; Nichol, S. T. Crimean-Congo hemorrhagic fever virus
1211 glycoprotein processing by the endoprotease SKI-1/S1P is critical for virus infectivity. *J.*
1212 *Virol.* **2007**, *81*, 13271-13276.
- 1213 137. Bergeron, É.; Zivcec, M.; Chakrabarti, A. K.; Nichol, S. T.; Albariño, C. G.; Spiropoulou,
1214 C. F. Recovery of Recombinant Crimean Congo Hemorrhagic Fever Virus Reveals a
1215 Function for Non-structural Glycoproteins Cleavage by Furin. *PLoS Pathog.* **2015**, *11*,
1216 e1004879.
- 1217 138. Flint, M.; Chatterjee, P.; Lin, D. L.; McMullan, L. K.; Shrivastava-Ranjan, P.; Bergeron,
1218 É.; Lo, M. K.; Welch, S. R.; Nichol, S. T.; Tai, A. W.; Spiropoulou, C. F. A genome-
1219 wide CRISPR screen identifies N-acetylglucosamine-1-phosphate transferase as a
1220 potential antiviral target for Ebola virus. *Nat Commun* **2019**, *10*, 285.

- 1221 139. Yuan, S.; Chu, H.; Chan, J. F.; Ye, Z. W.; Wen, L.; Yan, B.; Lai, P. M.; Tee, K. M.;
 1222 Huang, J.; Chen, D.; Li, C.; Zhao, X.; Yang, D.; Chiu, M. C.; Yip, C.; Poon, V. K.; Chan,
 1223 C. C.; Sze, K. H.; Zhou, J.; Chan, I. H.; Kok, K. H.; To, K. K.; Kao, R. Y.; Lau, J. Y.;
 1224 Jin, D. Y.; Perlman, S.; Yuen, K. Y. SREBP-dependent lipidomic reprogramming as a
 1225 broad-spectrum antiviral target. *Nat Commun* **2019**, *10*, 120.
- 1226 140. Wang, R.; Simoneau, C. R.; Kulsuptrakul, J.; Bouhaddou, M.; Travisano, K. A.; Hayashi,
 1227 J. M.; Carlson-Stevermer, J.; Zengel, J. R.; Richards, C. M.; Fozouni, P.; Oki, J.;
 1228 Rodriguez, L.; Joehnk, B.; Walcott, K.; Holden, K.; Sil, A.; Carette, J. E.; Krogan, N. J.;
 1229 Ott, M.; Puschnik, A. S. Genetic Screens Identify Host Factors for SARS-CoV-2 and
 1230 Common Cold Coronaviruses. *Cell* **2021**, *184*, 106-119.e14.
- 1231 141. Dias, S. S. G.; Soares, V. C.; Ferreira, A. C.; Sacramento, C. Q.; Fintelman-Rodrigues,
 1232 N.; Temerozo, J. R.; Teixeira, L.; Nunes da Silva, M. A.; Barreto, E.; Mattos, M.; de
 1233 Freitas, C. S.; Azevedo-Quintanilha, I. G.; Manso, P. P. A.; Miranda, M. D.; Siqueira, M.
 1234 M.; Hottz, E. D.; Pão, C. R. R.; Bou-Habib, D. C.; Barreto-Vieira, D. F.; Bozza, F. A.;
 1235 Souza, T. M. L.; Bozza, P. T. Lipid droplets fuel SARS-CoV-2 replication and production
 1236 of inflammatory mediators. *PLoS Pathog.* **2020**, *16*, e1009127.
- 1237 142. Lee, W.; Ahn, J. H.; Park, H. H.; Kim, H. N.; Kim, H.; Yoo, Y.; Shin, H.; Hong, K. S.;
 1238 Jang, J. G.; Park, C. G.; Choi, E. Y.; Bae, J. S.; Seo, Y. K. COVID-19-activated SREBP2
 1239 disturbs cholesterol biosynthesis and leads to cytokine storm. *Signal Transduct Target*
 1240 *Ther* **2020**, *5*, 186.
- 1241 143. Sohrabi, Y.; Reinecke, H.; Godfrey, R. Altered Cholesterol and Lipid Synthesis Mediates
 1242 Hyperinflammation in COVID-19. *Trends Endocrinol Metab* **2021**, *32*, 132-134.
- 1243 144. Hyrina, A.; Meng, F.; McArthur, S. J.; Eivemark, S.; Nabi, I. R.; Jean, F. Human
 1244 Subtilisin Kexin Isozyme-1 (SKI-1)/Site-1 Protease (S1P) regulates cytoplasmic lipid
 1245 droplet abundance: A potential target for indirect-acting anti-dengue virus agents. *PLoS*
 1246 *One* **2017**, *12*, e0174483.
- 1247 145. Blanchet, M.; Sureau, C.; Guevin, C.; Seidah, N. G.; Labonte, P. SKI-1/S1P inhibitor PF-
 1248 429242 impairs the onset of HCV infection. *Antiviral Res.* **2015**, *115*, 94-104.
- 1249 146. Olmstead, A. D.; Knecht, W.; Lazarov, I.; Dixit, S. B.; Jean, F. Human subtilase SKI-
 1250 1/S1P is a master regulator of the HCV Lifecycle and a potential host cell target for
 1251 developing indirect-acting antiviral agents. *PLoS. Pathog.* **2012**, *8*, e1002468.
- 1252 147. Merino-Ramos, T.; Jiménez de Oya, N.; Saiz, J. C.; Martín-Acebes, M. A. Antiviral
 1253 Activity of Nordihydroguaiaretic Acid and Its Derivative Tetra-O-Methyl
 1254 Nordihydroguaiaretic Acid against West Nile Virus and Zika Virus. *Antimicrob Agents*
 1255 *Chemother* **2017**, *61*.
- 1256 148. Uchida, L.; Urata, S.; Ulanday, G. E.; Takamatsu, Y.; Yasuda, J.; Morita, K.; Hayasaka,
 1257 D. Suppressive Effects of the Site 1 Protease (S1P) Inhibitor, PF-429242, on Dengue
 1258 Virus Propagation. *Viruses.* **2016**, *8*, E46.
- 1259 149. Kleinfelter, L. M.; Jangra, R. K.; Jae, L. T.; Herbert, A. S.; Mittler, E.; Stiles, K. M.;
 1260 Wirchnianski, A. S.; Kielian, M.; Brummelkamp, T. R.; Dye, J. M.; Chandran, K.
 1261 Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for
 1262 Hantavirus Membrane Fusion. *mBio* **2015**, *6*, e00801.
- 1263 150. Pasquato, A.; Kunz, S. Novel drug discovery approaches for treating arenavirus
 1264 infections. *Expert Opin. Drug Discov.* **2016**, *11*, 383-393.

- 1265 151. Elagoz, A.; Benjannet, S.; Mammabassi, A.; Wickham, L.; Seidah, N. G. Biosynthesis
1266 and cellular trafficking of the convertase SKI-1/S1P: ectodomain shedding requires SKI-
1267 1 activity. *J. Biol. Chem.* **2002**, 277, 11265-11275.
- 1268 152. Pasquato, A.; Cendron, L.; Kunz, S. Cleavage of the Glycoprotein of Arenaviruses.
1269 *Activation of Viruses by Host Proteases* **2018**, 47-70.
- 1270 153. Bestle, D.; Heindl, M. R.; Limburg, H.; Van Lam van, T.; Pilgram, O.; Moulton, H.;
1271 Stein, D. A.; Harde, K.; Eickmann, M.; Dolnik, O.; Rohde, C.; Klenk, H. D.; Garten,
1272 W.; Steinmetzer, T.; Böttcher-Friebertshäuser, E. TMPRSS2 and furin are both essential
1273 for proteolytic activation of SARS-CoV-2 in human airway cells. *Life Sci Alliance* **2020**,
1274 3.
- 1275 154. Anderson, E. D.; Molloy, S. S.; Jean, F.; Fei, H.; Shimamura, S.; Thomas, G. The ordered
1276 and compartment-specific autoproteolytic removal of the furin intramolecular chaperone
1277 is required for enzyme activation. *J. Biol. Chem.* **2002**, 277, 12879-12890.
- 1278 155. Ginefra, P.; Filippi, B. G. H.; Donovan, P.; Bessonard, S.; Constam, D. B.
1279 Compartment-Specific Biosensors Reveal a Complementary Subcellular Distribution of
1280 Bioactive Furin and PC7. *Cell Rep* **2018**, 22, 2176-2189.
- 1281 156. Ye, J.; Rawson, R. B.; Komuro, R.; Chen, X.; Dave, U. P.; Prywes, R.; Brown, M. S.;
1282 Goldstein, J. L. ER stress induces cleavage of membrane-bound ATF6 by the same
1283 proteases that process SREBPs. *Molecular of the Cell* **2000**, 6, 1355-1364.
- 1284 157. Yuan, J.; Cai, T.; Zheng, X.; Ren, Y.; Qi, J.; Lu, X.; Chen, H.; Lin, H.; Chen, Z.; Liu, M.;
1285 He, S.; Chen, Q.; Feng, S.; Wu, Y.; Zhang, Z.; Ding, Y.; Yang, W. Potentiating CD8(+)
1286 T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling
1287 and signaling. *Protein Cell* **2021**, 12, 240-260.
- 1288 158. He, Z.; Khatib, A. M.; Creemers, J. W. M. Loss of the proprotein convertase Furin in T
1289 cells represses mammary tumorigenesis in oncogene-driven triple negative breast cancer.
1290 *Cancer Lett.* **2020**, 484, 40-49.
- 1291 159. Rufer, A. C. Drug discovery for enzymes. *Drug Discov. Today* **2021**.
- 1292 160. Krammer, F.; Smith, G. J. D.; Fouchier, R. A. M.; Peiris, M.; Kedzierska, K.; Doherty,
1293 P. C.; Palese, P.; Shaw, M. L.; Treanor, J.; Webster, R. G.; García-Sastre, A. Influenza.
1294 *Nat Rev Dis Primers* **2018**, 4, 3.
- 1295 161. Kido, H.; Okumura, Y.; Takahashi, E.; Pan, H. Y.; Wang, S.; Chida, J.; Le, T. Q.; Yano,
1296 M. Host envelope glycoprotein processing proteases are indispensable for entry into
1297 human cells by seasonal and highly pathogenic avian influenza viruses. *J. Mol. Genet.*
1298 *Med.* **2008**, 3, 167-75.

1299